Mitochondrial dysfunction in human pathologies

María Monsalve^{1,2,3}, Sara Borniquel^{1,2,3}, Inmaculada Valle^{1,2,3}, and Santiago Lamas^{1,2,3}

¹ Centro de Investigaciones Biológicas (Consejo Superior de Investigaciones Científicas). Ramiro de Maeztu 9, 28040, Madrid Spain, ² Centro Nacional de Investigaciones Cardiovasculares (Instituto de Salud Carlos III), Melchor Fernandez Almagro 3, 28029, Madrid, Spain, ³ Instituto “Reina Sofía” de Investigaciones Nefrológicas, Spain

TABLE OF CONTENTS

1. Abstract	
2. Introduction	
3. Mitochondrial oxidative stress protection system.	
3.1. Detoxification enzymes	
3.1.1. Mn-SOD	
3.1.2. Catalase	
3.1.3. Peroxiredoxins	
3.1.4. Thioredoxin and thioredoxin reductase	
3.1.5. Glutathione peroxidase and other glutathione related systems	
3.2. Other protection systems	
3.2.1. UCP-2	
3.2.2. Heat shock proteins (HSP)	
4. Transcription factors	
4.1. Nrf1 and Nrf2	
4.2. AP-1	
4.3. NFkappaB	
4.4. HIF-1	
4.5. PPARs	
4.6. Foxo3a	
4.7. PGC-1alpha	
5. Nitric oxide	
5.1. Direct effects	
5.2. Indirect effects	
6. Diseases	
6.1. Neurodegenerative diseases	
6.1.1. Parkinson's disease	
6.1.2. Huntington's disease	
6.1.3. Alzheimer's disease	
6.1.4. Epilepsy	
6.1.5. Friedreich ataxia (FRDA)	
6.2. Cancer and ageing	
6.2.1. Cancer	
6.2.2. Aging	
6.3. Diabetes, atherosclerosis and ischemia reperfusion injury	
6.3.1. Diabetes	
6.3.2. Atherosclerosis	
6.3.3. Ischemia reperfusion injury	
7. Conclusions and perspectives	
8. Acknowledgments	
9. References	

1. ABSTRACT

The integrity of mitochondrial function is fundamental to cell life. The cell demands for mitochondria and their complex integration into cell biology, extends far beyond the provision of ATP. It follows that disturbances of mitochondrial function lead to disruption of cell function, expressed as disease or even death. Mitochondria are major producers of free radical species and also

possibly of nitric oxide, and are, at the same time, major targets for oxidative damage. In this review we consider recent developments in our knowledge of how the mitochondrial production of reactive oxygen species (ROS) plays a critical role in several major human pathologies. We will also consider recent advances in our understanding of the molecular mechanisms involved in mitochondrial ROS detoxification.

Figure 1. Main mitochondrial ROS detoxification enzymes.

2. INTRODUCTION

Mitochondria have been considered the powerhouse of the living cell. Their main function is the generation of energy in the form of the molecule ATP, a process that takes place through oxidative phosphorylation (1, 2). But, mitochondria are not just providers of energy, they are involved in many other aspects of cell physiology, the best known being calcium signaling, and programmed cell death (apoptosis) (3).

Generation of reactive oxygen species (ROS) in mitochondria is a consequence of the action of the electron transfer associated with oxidative phosphorylation that generates unpaired electrons. It has been estimated that 1-2% of the electrons that travel along the electron transfer (ETC) react with molecular oxygen (O_2) to produce the anion superoxide (O_2^-) a highly reactive free radical species. The superoxide anion-radical is readily converted to ROS, such as hydrogen peroxide (H_2O_2) and hydroxyl radicals ($HO^\bullet$). There is no question that mitochondria are the major source of oxygen free radical generation in most cell types, except perhaps for macrophages, which express an NADPH oxidase that generates massive amounts of O_2^- after stimulation.

The chemical species called ROS are able to cause lipid peroxidation and damage to cell membranes, proteins and DNA, so that mitochondria represent not only a major source of ROS generation, but also a major target of ROS induced damage. The high rate of mitochondrial DNA (mtDNA) mutation (10-fold higher than in the nuclear DNA (nDNA)) will eventually result in the accumulation of mutations in mitochondrial proteins. Defective proteins will in turn exacerbate mitochondrial dysfunction, increase production of ROS, and reduce mitochondrial energy production.

Mitochondria are equipped with an armamentarium of antioxidant defenses (Figure 1) and contain a high concentration of glutathione, mainly reduced glutathione (GSH) fundamental to cell survival. Although still not thoroughly investigated, important members of this system are Mn superoxide dismutase (Mn-SOD),

peroxiredoxins III and V (Prx3, Prx5), mitochondrial thioredoxin (Trx2) and, mitochondrial thioredoxin reductase (TrxR2), mitochondrial glutaredoxin (Grx2a), mitochondrial glutaredoxin reductase (mtGrxR), glutathion peroxidase 4 (GPX4), uncoupling protein 2 (UCP-2), and a specific set of heat shock proteins.

In general, the leak of electrons from the electron transfer chain seems to be increased by an increase in mitochondrial potential and decreased with mitochondrial depolarization. Provided that mitochondrial activity can vary greatly, as well as electron transfer efficiency as phosphorylation coupling, mitochondrial ROS production can change rapidly in various physiological and pathological conditions. Therefore the oxidative protection system must be under tight regulatory control. Several transcription factors, and biomolecules like nitric oxide (NO) have been proposed to modulate the expression of at least one member of the system, but until recently a coordinated regulation had not been described. Peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC-1alpha), a transcriptional coactivator well known as a key regulator of mitochondrial biogenesis and lipid catabolism, has been shown to be a master regulator of the mitochondrial oxidative stress protection system in endothelial cells, a role that is likely to play in other cells systems, particularly those with high metabolic rates where PGC-1alpha has a crucial role in the control of energy metabolism.

Mutations in mitochondrial genes have been shown to cause many different genetic diseases (*i.e.* LHON dystonia, Leigh's disease) (4). Phenotypes of mitochondrial diseases can be both diverse and overlapping, that is, the same mutation can produce quite different phenotypes, and different mutations can produce similar phenotypes. Variations in the percentage of mutant mtDNAs between patients must change the ATP output and cause the variation in clinical symptoms. Hence patients are generally classified by genetic defect rather than by clinical manifestation (5). However, the most common pathologies associated with mitochondria are not hereditary but associated with age and with the physiological or pathological production of mitochondrial ROS.

Major pathologies for which the role played by mitochondrial dysfunction and ROS production has been clearly established include all the common neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease, epileptic seizures, FRDA), atherosclerosis, diabetes, ischemia-reperfusion injury, cancer and aging.

Therefore, the knowledge of the causes that result in an excessive production of mitochondrial ROS and/or the failure of its detoxification systems are necessary for the development of new therapeutic strategies. In order to understand the pathologies associated with mitochondrial dysfunction, one of the fundamental milestones is to underscore the differences in the susceptibility of different cell types to mitochondrial oxidative stress. The factors responsible for this variability include the inner

mitochondrial membrane lipid composition and /or the oxidant/antioxidant balance, (*i.e.* superoxide dismutase) and/or heat shock protein activity and expression as well as the glutathione status. It is also important to point out that most of these pathologies involve tissues with high metabolic rates and mitochondrial content.

3. MITOCHONDRIAL OXIDATIVE STRESS PROTECTION SYSTEM

ROS include a family of chemically reactive molecules derived from O_2 . Some of these molecules are extremely reactive, such as $HO^\cdot$, while some others are less reactive like $O_2^\cdot$ and H_2O_2 . Intracellular free radicals (free, low molecular weight molecules with an unpaired electron, are often ROS and vice versa, and the two terms are commonly exchanged). Free radicals and ROS can readily react with most biomolecules, starting a chain reaction of free radical formation. In order to interrupt this chain reaction, a newly formed radical must either react with another free radical, with cancellation of the unpaired electrons, or react with a free radical scavenger, also known as a chain-breaker or primary antioxidant.

3.1 Detoxification enzymes

3.1.1. Mn-SOD

Superoxide anion is generated from molecular O_2 by the addition of one electron. It is not highly reactive, and it lacks the ability to penetrate lipid membranes and is therefore enclosed in the compartment where it was produced. The formation of $O_2^\cdot$ takes place spontaneously, especially in the electron-rich aerobic environment in the vicinity of the inner mitochondrial membrane containing the respiratory chain. Although $O_2^\cdot$ is not an effective oxidant, it impairs mitochondrial function by oxidizing the Fe-S centers of various enzymes. In addition, $O_2^\cdot$ can react with NO to produce peroxynitrite, an extremely powerful oxidant.

Two molecules of $O_2^\cdot$ rapidly dismutate to H_2O_2 in the presence of the superoxide dismutase enzymes (SOD). Mn-SOD is the SOD isoform that localizes in the mitochondrial matrix. It is an essential protein (*sod2* knock-out mice die soon after birth) (7). Several lines of evidence support the idea that Mn-SOD has tumor suppressor activity. In general, reduced levels of Mn-SOD are observed in many types of human tumors, whereas overexpression of Mn-SOD suppresses tumorigenicity. Life-long reduction in Mn-SOD activity (in heterozygotic *sod2*^{+/−} mice) results in a much higher incidence of cancer (7). It has been postulated that Mn-SOD anti tumorigenic activity is a direct consequence of the relieved mitochondrial oxidative stress caused by $O_2^\cdot$, however it must be taken into account that Mn-SOD generates H_2O_2 and therefore can generate a different type of oxidative stress in the absence of the corresponding H_2O_2 scavengers. Nevertheless, Mn-SOD seems to behave mainly as an antioxidant in most biological settings. Evidence supporting an antioxidant role for Mn-SOD include studies with transgenic mice over-expressing Mn-SOD in various tissues, they show increased tolerance to several oxidative stress situations including ischemia-reperfusion injury (8),

streptozotocin induced beta-cell injury (9), 6-hydroxydopamine injury to dopaminergic neurons (10), and adriamycin and paraquat toxicity (11). Importantly, the *sod2* gene is transcriptionally up-regulated by oxidative stress.

3.1.2. Catalase

Hydrogen peroxide is not a free radical, but it is highly important much because it is an essential intermediate in the formation of more reactive ROS molecules, particularly of hydroxyl radical ($HO^\cdot$) via Fenton reaction with transition metals. It also has the ability to penetrate biological membranes, and therefore H_2O_2 generated in the mitochondria can readily diffuse into the cytosol. Hydrogen peroxide is removed by at least three antioxidant enzyme systems, catalases, glutathione peroxidases and peroxiredoxins.

Catalase is mainly located in peroxisomes, where it catalyzes the dismutation of H_2O_2 to H_2O and O_2 . It is likely to be responsible at least in part of the clearance of the H_2O_2 that is produced in the mitochondria and leaks out into the cytoplasm. The oxidative stress protective role of catalase is well established. Deficiencies in catalase activity are associated with oxidative stress related pathologies, and increased oxidant sensitivity. Cancer cells typically show reduced catalase levels. Inherited deficiency in catalase is associated with diabetes mellitus, hypertension and altered lipid, carbohydrate and homocysteine metabolism (12). Mice lacking catalase have increased sensitivity to various oxidants (13). In contrast, increased catalase levels are generally protective. Transgenic mice over-expressing catalase in various tissues show increased tolerance to ischemia-reperfusion injury and oxidative stress inducing agents such as adriamycin, paraquat (14) and streptozotocin induced beta-cell injury (9). Apolipoprotein E deficient (*ApoE*^{−/−}) mice that over-express catalase show reduced atherosclerosis plaque formation (15), probably because over-expression of catalase in vascular smooth muscle cells (VSMC) inhibits H_2O_2 induced cell proliferation (a process that takes place during plaque formation) (16). Most importantly targeting of catalase to mitochondria extended life span in mice by 20% (17).

3.1.3. Peroxiredoxins

It is a family of enzymes capable of directly reducing hydroperoxides (*i.e.* H_2O_2 and different alkyl hydroperoxides). In the mitochondria of mammalian cells there are at least two members, Prx3, and Prx5. Prx3 contains a mitochondrial localization sequence, is found exclusively in the mitochondrion and uses mitochondrial thioredoxin-2 (Trx2) as the electron donor for its peroxidase activity (18). Prx3 is induced by oxidants in the vascular endothelial cell system and is thought to play a role in the antioxidant defense system and homeostasis within the mitochondria (19). Prx5 has three isoforms originated by alternative splicing, one is present in the mitochondria, another in the nucleus and the third in peroxisomes. mtPrx5 is comparatively poorly characterized than Prx3, however the information available so far point to a very similar role to that of Prx3. It uses Trx2 as electron donor (20-24).

Both Prx3 and Prx5 are over-expressed in different forms of cancer (25, 26), including the best characterized breast cancer (27, 28). This observation contrast with the above mentioned reduced activity of both Mn-SOD and catalase in human malignancies. It has been proposed that both Prx3 and Prx5 protect malignant cells from H₂O₂ toxicity.

Whereas low levels of H₂O₂ are essential for cell growth, elevated levels of H₂O₂ are toxic to the cell and can lead to apoptosis. Human solid tumors frequently show regions of hypoxia, and suffer elevated levels of H₂O₂. This situation can explain why Prx over-expression can be beneficial to cancer cells. Elevated Prx3 levels help to scavenge the excess H₂O₂ and protect cells from H₂O₂ induced apoptosis (29). Similarly Prx3 protects cells during hypoxia (30), a situation that induces the mitochondrial production of ROS by the disruption of oxidative phosphorylation (31).

However, in physiological conditions, low levels of H₂O₂ are an important cell proliferation signal. In these conditions Prx3 inhibits the growth stimulatory effects of H₂O₂. This effect can be crucial in the cardiovascular system where metabolic dysfunction in the endothelium generates an oxidative stress situation that initiates atherosclerosis processes. In this scenario excessive production of H₂O₂ by stressed endothelial cells promotes proliferation of VSMC, a process that could be prevented by Prx3.

3.1.4. Thioredoxin and thioredoxin reductase

The thioredoxin system consists of the two antioxidant oxidoreductase enzymes thioredoxin (Trx) and thioredoxin reductase (TrxR). The latter catalyzes the reduction of the active site disulfide in Trx using NADPH₂ and, among other functions, reduced Trx is a general protein disulfide reductant, and a specific electron donor for many Prx.

Trx2 is located in mitochondria (24). The Trx2 system includes Prx3, Trx2 and TrxR2. Prx3 utilizes Trx2 as electron donor, and TrxR2 uses NADPH₂ to regenerate reduced Trx. All three are ubiquitously expressed, but are found at the highest levels in metabolically active tissues, such as heart (32), brain and liver (33, 34). Yeast mutants of any of these three proteins support their role in the protection against oxidative stress (35). Trx2 over-expression can protect cells from oxidant-induced apoptosis and increase the mitochondrial membrane potential (36, 37). Trx2^{-/-} mice show early embryonic lethality. The timing of embryonic lethality coincides with the maturation of the mitochondria, since they begin oxidative phosphorylation during that stage of embryogenesis (38). Conditional Trx2 deficient cells show that upon loss of Trx2 cells show and increased accumulation of ROS, decreased mitochondrial GSH levels and induction of apoptosis (39). Trx2 is up regulated by ROS (40-42), and this regulation could be involved in preconditioning-induced protection from cardiac and neuronal ischemia.

TrxR reduces not only the disulfide in oxidized Trx, but also some other protein disulfides or a wide spectrum of oxidized low molecular weight compounds, playing an important role in the regeneration of antioxidants. TrxR2 is located in mitochondria (43, 44). Deletion of TrxR2 results in embryonic lethality at day 13. These embryos have hematopoiesis deficiencies and are severely anemic, show increased apoptosis in the liver, and reduced cardiomyocyte proliferation, the cultured fibroblast are extremely sensitive to oxygen radicals. In order to investigate the putative role of mitochondrial dysfunction in the embryonic lethality, TrxR2 was specifically ablated in mice heart. These mice die shortly after birth of fatal dilated cardiomyopathy, a condition observed in Friedreich's ataxia and associated with mitochondrial oxidative stress (45). Over-expression of a dominant negative form of TrxR2 in HeLa cells results in a higher concentration of H₂O₂ (46), while over-expression of TrxR2 increases resistance to cytotoxicity induced by inhibition of the mitochondrial complex III.

3.1.5. Glutathione peroxidase and other glutathione related systems

The tri-peptide glutathione (γ-glutamyl-cysteinyl-glycine) is an endogenous antioxidant of great importance. GSH is required for the maintenance of the thiol redox status of the cell, protection against oxidative damage, detoxification of reactive metals and electrophiles, storage and transport of cysteine, DNA synthesis, cell cycle regulation and cell differentiation (47). The key functional element of glutathione is the cysteinyl moiety, which provides the reactive thiol group. ROS are reduced by GSH in the presence of GSH peroxidase (GPx). As a result GSH is oxidized to GSSG, which in turn is rapidly reduced back to GSH by GSSG reductase (GR) at the expense of NADPH. The redox cycle also aids in maintaining reduced protein and enzyme thiols. Without it, vulnerable cysteinyl residues of essential enzymes might remain oxidized, leading to changes in catalytic activity. Glutathione is also an excellent scavenger of lipid peroxidation products such as HNE and acrolein. Glutathione reacts with carbon atoms via nucleophilic attack on an electrophilic carbon, in a reaction catalyzed by glutathione S-transferase. GSH also has a high affinity for metal ions, and acts as a reductant in redox reactions involving metals. It also forms stable complexes with metals (mercury, lead, etc) and products of lipid peroxidation that can then be eliminated from the body.

Another class of proteins intimately related to GSH are the glutaredoxins (Grx) and glutaredoxin reductase (GrxR), with functions overlapping those of thioredoxin system, the major difference being that Grx can be reduced directly by GSH and is capable of reducing GSH mixed protein disulfides formed at oxidative stress.

Mitochondria have a high concentration of glutathione that must be imported from the cytosol via a specific carrier because it lacks the enzymes required for glutathione synthesis. Ethanol intake reduces the activity of the carriers (dicarboxylate and 2-oxoglutarate) in hepatic cells, sensitizing hepatocytes to oxygen radicals (48),

mitochondrial GSH depletion by beta-amyloid is associated with Alzheimer's disease (AD) (49, 50). Changes in redox balance in the mitochondria are directly associated with alterations in the GSH/GSS ratio, and the induction of mitochondria-mediated apoptosis (51).

The mitochondrial Grx2a (52) can use both GSH and TrxR2 as electron donors. It has been shown to play a role in the protection of thiols of mitochondrial proteins from formation of disulfides when the redox balance is altered in oxidative stress situations (53), and could also help to prevent cardiolipin oxidation and the initiation of the mitochondrial apoptotic cascade induced by agents like doxorubicin and 2-deoxy-D-glucose (54). It has also been proposed to act as a mitochondrial redox sensor that is activated when the glutathione pool becomes oxidized. (55). The mitochondrial glutathione reductase (mtGrxR) in an splice variant isoform of the gene coding for the cytoplasmic enzyme (56).

Phospholipids that are rich in unsaturated fatty acids, are particularly susceptible to ROS attack. The result is the formation of lipid hydroperoxides. This process is particularly relevant in mitochondria where the electron transfer chain produces O_2^- and H_2O_2 at the mitochondrial inner membrane (57). GPx1 is the major GPx isoform, and it is present in all tissues; 10% of GPx1 localizes to mitochondria (mtGPx1) where it has been considered the most important H_2O_2 metabolizing enzyme in mitochondria, a view that was recently challenged (58). GPx4 is also called PHGPx and has three isoforms originated by alternative splicing, one present in the mitochondria (L-form), where it markedly reduces the lipid hydroperoxides generated in biomembranes. GPx4 over-expression effectively prevents apoptosis induced by different stimuli, including oxidized low density lipoproteins (oxLDL), and cholesterol hydroperoxide (both important risk factors in atherosclerosis). It protects the mitochondrial lipid cardiolipin from oxidation and hence prevents the release of cytochrome c from the mitochondrial inner membrane. It also prevents the inactivation of the adenine nucleotide transporter that leads to the opening of the membrane transition pore (MTP), exit of cytochrome c and initiation of apoptosis (59-62). GPx4 also reduces the accumulation of mitochondrial H_2O_2 in cells treated with agents that generate mitochondrial stress. It has been proposed that Gpx4 is important for the protection of the damage associated with ischemia-reperfusion injury (63).

3.2 Other protection systems

3.2.1. UCP-2

It is a gated proton channel located in the mitochondria inner membrane, it decreases metabolic efficiency by dissociating substrate oxidation in the mitochondria from ATP synthesis.(64). Therefore, it can reduce the inner mitochondria membrane potential ($\Delta\psi$), reduce ATP synthesis, dissipate energy in the form of heat, and diminish the production of O_2^- . It was initially proposed to play a role in adaptive thermogenesis, however accumulated data support the notion that UCP-2 prevents the excessive production of O_2^- in mitochondria. In fact, O_2^- has been shown to induce the expression of UCP-2 (65). It

is also directly induced by H_2O_2 and under pathological conditions where excessive ROS production occurs (66-69). However, the transcriptional regulatory mechanisms are not fully elucidated, its expression is induced by PPARalpha, and PGC-1alpha and it seems that activation requires high glucose and FFA, a putative protective mechanism since both are likely to increase ROS production. UCP-2^{-/-} animals show increased free radical production in monocytes (70), UCP-2 deficiency in bone marrow precursors results in a significant increase in atherosclerotic plaque formation in mice (71). Its over-expression has been proposed to be protective from ROS in various cell types and tissues. Cells that over-express UCP-2 are more resistant to H_2O_2 treatments (72-74). UCP-2 over-expression also reduces lipid peroxidation at least in the brain (75), where it protects neurons against seizure and neuronal damage (76, 77). Over-expression in dopaminergic neurons protects from Parkinson-inducing agents (78). Furthermore, increased expression of human UCP-2 in the adult fly nervous system extends fly life span (77). Importantly, UCP-2 has also been proposed to control glucose dependent insulin secretion in beta-cells, through the reduction of ATP synthesis, and concomitantly has been proposed to play a role in the pathogenesis of diet-related type 2 diabetes.

3.2.2. Heat shock proteins (HSP)

In mammalian cells HSP synthesis is induced not only after hyperthermia, but also following a wide variety of stress conditions including oxidative stress (79), in fact it constitutes a fundamental mechanism necessary for cell survival under a wide array of toxic conditions that include mitochondrial oxidative stress (80). The induction of the heat shock response requires the activation and translocation to the nucleus of one or more heat shock transcription factors which control the expression of a set of protective heat shock proteins (81). The transcription factor HSF plays a crucial role in the transcriptional induction of HSP in stress conditions (82-84). Some of the best known HSPs include ubiquitin, Hsp10, Hsp27, Hsp32 (HO-1), Hsp47, Hsp60, Hsc70, Hsp70 (Hsp72), Hsp90 and Hsp100/105 (85). The important and well-characterized Hsp70 family includes Hsc70, Hsp70, and GRP75. They are protein chaperones, that bind to unfolded proteins and return them to their native conformation through an ATP dependent mechanism. Ubiquitin targets proteins to be degraded by the proteasome (86).

Mitochondrial oxidative stress has been shown to induce a heat shock response (87). Several HSP have been found in the mitochondria where they could play a protective role. Hsp60 directs the entry of proteins into the mitochondria (88), its yeast homologue has been proposed to protect from oxidative stress (89). Glucose-regulated protein 75 (GRP75) (90), prevents the accumulation of ROS in mitochondria (91). Hsp10 exerts its chaperone function with proteins within mitochondria (92). Hsp10 is required for the folding and assembly of proteins imported into the matrix compartment, and is involved in the sorting of certain proteins, such as the Rieske Fe/S protein, passing through the matrix en route to the intermembrane space. Both Hsp10 and Hsp60 have been shown to protect

mitochondrial function in ischemia-reperfusion (93). Hsp70 (Ssc1) regulates the entry and adequate folding in the mitochondria of proteins with Fe-S centers (94, 95) and is activated by Hsp40.

Hsp32 has three isoforms, HO-1, HO-2 and HO-3. HO-1 is the rate limiting enzyme in the production of bilirubin, a potent antioxidant. It catalyzes the specific oxidative cleavage of the heme molecule to form equimolar amounts of biliverdin and carbon monoxide (CO). HO-1 is rapidly up-regulated by oxidative and nitrosative stresses, as well as by glutathione depletion. Its promoter has an antioxidant responsive element (ARE) similar to other antioxidant enzymes (96).

4. TRANSCRIPTION FACTORS

All the above mentioned antioxidant defenses are induced by different stimuli in response to stress situations. Several transcription factors have been proposed to be activated in response to oxidative stress and/or modulate the expression of one or more protection genes. However until recently a specific and coordinated regulation of the mitochondrial system had not been described. The transcriptional coactivator PGC-1 α has been shown to play that role and to be directly regulated by the intracellular levels of NO. The activity of the transcription factors is also tightly controlled by the cellular redox state as evidenced by the protein Raf-1 that is necessary to keep several transcription factors in a reduced/active conformation (97).

4.1. Nrf1 and Nrf2

Basal and inducible expression of a number of antioxidant defense genes are in part regulated by a cis-acting DNA element known as the antioxidant responsive element, ARE, (98) that should be more properly called electrophyl response element, since it is present in genes that detoxify carcinogens, suggesting that induction through ARE is chemopreventive, and not closely related to mitochondrial processes (99). However, activation through ARE appears to be driven by conditions that promote intracellular oxidative stress and therefore must be taken into consideration. A number of transcription factors have been proposed to bind to ARE, but the most recent studies point to the CNC subfamily of bZIP proteins as mediators of ARE function (100). They appear to function as obligate heterodimers with other bZIP proteins.

Forced expression experiments of the bZIP proteins Nrf1 and Nrf2 suggest that they mediate ARE function (101). Nrf1^{-/-} mice show embryonic lethality but Nrf1 null cells have been isolated and shown to have an increased sensitivity to the toxic effects of oxidants than their wild type controls (102). Nrf2^{-/-} mice are viable but they show diminished expression of several phase 2 enzymes (detoxification of xenobiotics) and are sensitive to treatments that cause oxidative stress (103, 104). The analysis of double knock-out animals shows they have overlapping functions and are functionally redundant in mediating ARE function and oxidative stress defense (105). The mechanism of signal transduction from xenobiotics to

Nrf1 and Nrf2 has not been elucidated although it has been proposed to involve the activation and phosphorylation by PKC (106).

4.2. AP-1

The immediate early response expression of Jun and Fos (AP-1) controls the expression of many genes, and plays a central role in the control of cell proliferation and transformation. Among other stimuli, it is rapidly induced by H₂O₂, UV-C, UV-A, ionizing radiation etc. Its DNA binding activity is also induced by UV and H₂O₂ (99). Several signal transduction pathways and the direct action of oxidants on the proteins have been proposed to mediate their induction and activation. AP-1 has been shown to induce the expression of Mn-SOD (107), but the biological role of this regulation seems to be mainly related to the role played by Mn-SOD in tumor suppression (108, 109), and although it is possible that it is also relevant in the control of the cellular redox state, to date this possibility has not yet been tested.

4.3. NFkappaB

Nuclear factor kappa B (NFkappaB) plays a central role in the regulation of many genes involved in cellular defense mechanisms, apoptosis, pathogen defenses, immunological responses and expression of cytokines and cell adhesion molecules. ROS, generated in the mitochondria, have been proposed as the intermediate second messengers to the activation of NFkappaB by tumor necrosis factor alpha (TNFalpha) and interleukin 1 (IL-1). NFkappaB activation can in fact be directly mediated by H₂O₂ and hydroperoxides (99). NFkappaB has been shown to induce Mn-SOD (110, 111), the biological role of this induction is not completely understood but it might be related with the induction of pro-survival signals in inflammatory situations where high levels of ROS are generally produced (112-114).

It is a well-established fact that females live longer than males. Mitochondria from females produce less H₂O₂ and have higher levels of Mn-SOD and GPx. Estrogen is responsible for these differences. Interestingly, its effects do not seem to be mediated by the nuclear receptor ER, but by its interaction with a membrane receptor that signals to exert NFkappaB activation (115).

4.4. HIF-1

Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that governs cellular responses to reduced O₂ availability, a situation that is also prone to production of mitochondrial ROS. Upon O₂ deprivation the degradation rate of the HIF-1 alpha subunit turn-over is reduced and the protein stabilized. Importantly it has been recently shown that HIF-1 stabilization requires mitochondrial ROS and is inhibited in the presence of high levels of GPx or catalase (116, 117). HIF-1 has also been proposed to up-regulate the Mn-SOD promoter although the biological significance of this regulation has not been established (118).

4.5. PPARs

The connection between peroxisome proliferator activated receptors (PPARs) and oxidative stress is still a

Figure 2. High glucose increases mitochondrial ROS production leading to oxidative stress and endothelial dysfunction. PGC-1alpha induction activates mitochondrial function and increases its ROS detoxification capacity. Over-expression of PGC-1alpha in high glucose conditions prevents oxidative stress and endothelial dysfunction.

non solved issue. PPARalpha has been shown to induce ROS production in liver where it can result in increased carcinogenesis risk (119). However several reports also point to PPARs as involved in the regulation of the inflammatory response, and possibly in the control of ROS production (120). Reports suggesting that PPARs can induce UCP-2 promoter are also suggestive of the involvement of PPARs in the control of cellular ROS production (121, 122).

4.6. Foxo3a

Foxo3a is the DNA binding transcription factor that up to date has been more clearly and directly involved in the protection against mitochondrial oxidative stress. Foxo3a is the human homolog of Daf-16 from *C. Elegans*, genetic data in *C. elegans* show that Daf-16 increases life span in response to reduced insulin/IGF-1 signaling (123), and has also been shown to modulate, metabolism and fertility in the worm. Foxo3a can protect from H_2O_2 toxicity by directly inducing Mn-SOD and catalase genes (124). Regulation by insulin/IGF-1 activates protein kinase B (AKT) that phosphorylates Foxo3a and directs its exclusion from the nucleus (125). Therefore, Foxo3a is inactivated in high insulin (high glucose) conditions where lipid metabolism and mitochondrial activity are low. Foxo3a is also sensitive to redox status through its interaction with p66shcA (126). ERK directly phosphorylates p66shcA. In response to H_2O_2 , inhibition of ERK activation represses p66shcA-dependent phosphorylation of Foxo3a, and facilitates Foxo3a entry into the nucleus (127). Importantly Foxo3a is also able to

induce cell cycle arrest in stress conditions supporting the role of Foxo3a in cell survival under stress conditions.

4.7. PGC-1alpha

The discovery that caloric restriction is associated with increased longevity, was the first indicator of the important connection between the regulation of oxidative metabolism or in other words, mitochondrial function and the oxidative stress protection systems. The idea is at first sight paradoxical, since increased mitochondrial activity should be associated with an elevated production of ROS in the mitochondria, however, cells that are more dependent on oxidative phosphorylation than on glycolysis, were more protected against oxidative stress, had lower ROS levels and hence aged more slowly. The clue to this apparent paradox is very likely that the activation of oxidative metabolism and the mitochondrial function goes hand in hand with the induction of the ROS protection system. The transcription factor responsible for this coordinated regulation is PGC-1alpha. PGC-1alpha was originally characterized as an inducer of mitochondrial proliferation (128), it was later found to be also an activator of lipid catabolism (129) and liver gluconeogenesis (130).

Two important characteristics of PGC-1alpha are its tissue-specific expression pattern and its inducibility by particular signals (131, 132). PGC-1alpha is selectively expressed in tissues that have high energy demands and are rich in mitochondria, such as heart, skeletal muscle, brown adipose, kidney, liver and brain (128, 130, 133, 134). Its activity and expression levels are induced by cold exposure, fasting and, exercise (133, 135, 136). Signaling pathways associated with these stimuli (p38 MAP kinase, beta-adrenergic/cAMP, nitric oxide, AMP kinase and Ca^{2+} -calmodulin kinase) activate PGC-1alpha and its downstream target genes by increasing PGC-1alpha expression or transactivation function (137-140). Previous studies using gain-of-function strategies (adenoviral-mediated or transgenic expression of PGC-1alpha in cultured cells and in vivo) have demonstrated that the transcriptional coactivator PGC-1alpha promotes the activation of mitochondrial biogenesis and increases cellular respiration (128, 135, 141).

On the other hand, studies in PGC-1alpha deficient mice have demonstrated the critical role for PGC-1alpha in the control of cellular energy metabolism. Oxidative metabolism and mitochondrial function are impaired in several tissues in mice lacking PGC-1alpha, fewer and smaller mitochondria were found in slow twitch muscles. Accordingly, a reduction in the expression of nuclear genes encoding proteins involved in mitochondrial electron transfer chain (cytochrome c and cytochrome oxidase), the beta subunit of ATP synthase, as well as a reduction of the expression of Tfam A (that directs the replication of the mitochondrial DNA) were found in knockout PGC-1alpha animals (142, 143).

Our group has recently proposed that PGC-1alpha coordinately regulates several key genes involved in the protection against mitochondrial oxidative stress, Mn-SOD, catalase, UCP-2, Prx3, Prx5, Trx2 y TrxR2 (Figure 2).

Cells that over-express PGC-1 α produce less ROS and are protected against oxidative stress agents like high glucose and H₂O₂ (144).

5. NITRIC OXIDE

NO is a diatomic free radical which is a gas at room temperature, making it highly diffusible within the cell. Its major target is the soluble guanylate cyclase (sGC), an enzyme whose activation increases the concentration of cGMP, and the activation of the cGMP dependent kinase G (PKG). NO/cGMP/PKG signaling pathway was originally identified as playing a key role in blood pressure regulation promoting smooth muscle relaxation, (145). It was later found to play other important roles in endothelial physiology and maintenance, as well as in regulation of platelet aggregation, and peripheral and central neurotransmission (146). More recently it has been proposed to control mitochondrial number (147, 148).

NO is produced from arginine and O₂ through a reaction catalyzed by nitric oxide synthases (NOS). Traditionally, three types of NOS have been described: iNOS (inducible), nNOS (neuronal) and eNOS (endothelial). It has also been proposed the existence of a mitochondrial NOS (mtNOS), that is not encoded by an independent gene but could be an alternative spliced product or specifically modified version of one or more of the classical enzymes (149). This hypothesis is intriguing since NO has multiple targets within the organelle. Although the existence of mtNOS is still under debate there are interesting findings. First of all, it seems that eNOS is attached to the outer mitochondrial membrane, which indicates that mitochondria may regulate NOS activity and conversely, eNOS may regulate mitochondrial respiration. The idea that mitochondria themselves are capable of producing NO is an important concept in several physiological and pathological mechanisms. Although mitochondria are not expected to release physiological relevant levels of NO, NO readily reacts with O₂⁻ to produce peroxynitrite a highly reactive compound with important biological activities (150).

A large body of evidence suggest that NO plays a dual role acting both as a pro-oxidant and as antioxidant in different biological settings. Most evidence points to peroxynitrite as the mayor mediator of NO prooxidant effects while how NO mediates its antioxidant effects has been a serious matter of controversy, although most evidence points to a putative role played by the mitochondria. We have recently shown that NO can modulate PGC-1 α expression both positively and negatively and hence regulate the expression levels of the mitochondrial detoxification system (our unpublished results). Both the prooxidant and antioxidant effects of NO have been shown to be highly relevant in pathologies such as atherosclerosis, neurodegenerative diseases, and ischemia reperfusion. The dual effects of NO depend on one hand on the levels of NO, since low levels tend to be protective, while high concentrations are normally toxic to the cells. On the other hand, NO has direct effects (those that are direct consequence of its chemistry) and the most

important, indirect effects (those mediated by the activation of the sGC/PKG pathway).

5.1. Direct effects

One of the most significant biological reactions of NO is with transition metals like Fe resulting in NO-metal complexes. NO can react with heme iron containing proteins, a reaction that is highly reversible, or with non heme iron, a situation that results in the permanent inactivation of the target enzyme. Putative heme protein targets for NO include catalase, cytochrome oxidase (151), hemoglobin and peroxidase. NO reaction with non-heme iron, such as iron-sulfur clusters has been described with enzymes like NADH-ubiquinone oxidoreductase, cis-aconitase and NADH: succinate oxidoreductase. However the biological relevance of these reactions is still to be determined, particularly for the non-heme reactions with low K_m that depend on extremely high NO concentrations.

Nitric oxide affects the mitochondrial respiratory chain through: a) inhibition of the cytochrome oxidase activity, b) inhibition of the electron transfer between cytochromes *b* and *c* and c) inhibition of NADH-dehydrogenase activity (152).

Inhibition of cytochrome oxidase activity. Cytochrome oxidase or complex IV is the terminal enzyme of the mitochondrial respiratory chain that is responsible for over 95% of cellular O₂ consumption in mammals and that is inhibitable by NO in a direct interaction with the enzyme (153, 154). The inhibition takes place as NO competes with O₂ for the binding site of the enzyme at the reactive center, increasing the operative K_m of O₂ for the enzyme. A consequence of cytochrome oxidase inhibition is a reduction of the capacity to use O₂ in cells, a phenomenon known as 'metabolic hypoxia' (155). Inhibition of mitochondrial respiration occurs in a reversible and, concentration-dependent manner (151, 156). The degree of inhibition of cytochrome oxidase activity by NO depends on the O₂ concentration in the reaction medium (152). The function of the interaction of NO with cytochrome oxidase is still a matter of controversy. Brown (153) proposed that NO inhibition of cytochrome oxidase might be involved in the physiological regulation of O₂ consumption rate. Shiva (157) has hypothesized that NO through the inhibition of complex IV increases the production of O₂⁻ by the electron transfer chain and the formation of H₂O₂. This increased ROS production can damage cellular systems (158), a phenomenon proposed as to take place in inflammatory conditions or in neurodegenerative diseases. Taking into account the affinity (association constant, K_a = 1-10 pM) of the reaction of NO with cytochrome oxidase, which is similar to the one for the NO interaction with sGC, it follows that both NO-heme interaction are likely to occur under physiological conditions.

Inhibition of electron transfer between cytochromes *b* and *c*. The inhibition of electron transfer in ubiquinol-cytochrome *c* reductase (complex III) by NO results in an increased rate of O₂⁻ production in submitochondrial particles and in an increased rate of H₂O₂

production in whole mitochondria. The phenomenon is reversible and is not affected by the O_2/NO ratio (152).

Inhibition of NADH-dehydrogenase activity. Nitric oxide inhibits the mitochondrial respiration chain at this level through secondary mediators, likely through peroxynitrite ($ONOO^-$) (159). The process results in the inhibition of the electron transfer activity of NADH-ubiquinone reductase (complex I), and of related activities, such as malate-glutamate dependent mitochondrial respiration or NADH-cytochrome c reductase activity. This phenomenon takes place after relatively prolonged exposure of cells to NO and in conditions of reduced glutathione levels (152).

5.2. Indirect effects

Several observations support the notion that NO antioxidant properties are not restricted to the direct action of NO but are likely to be largely dependent on changes in gene expression and/or protein activity elicited indirectly by NO. Indeed, the induction of eNOS expression by H_2O_2 (160) has been suggested to protect trained muscles from oxidative stress (161). Similarly, NO preconditioning prevents oxidative damage after myocardial infarction (162). These data suggest that a relatively limited ROS production is necessary to induce eNOS and the ROS detoxification systems.

It has been proposed that NO acts as a positive regulator for cells and tissue metabolism. Long-term exposure of cells to NO induces mitochondrial biogenesis. This process involves increased expression of PGC-1 α , nuclear respiratory factor 1 (NRF-1) and mitochondrial transcription factor A (Tfam A) (147, 148).

Experiments from our laboratory have shown that PGC-1 α over-expression not only promotes mitochondrial activity but also results in the induction of genes involved in mitochondrial oxidative stress protection. In turn, this results in reduced levels of ROS production in cells that express PGC-1 α (144). These results led us to investigate if NO could regulate the mitochondrial oxidative protection system through the regulation of PGC-1 α expression. We found that endothelial cells treated with NO donors showed an up-regulation in the mRNA levels of PGC-1 α and its target genes, including the mitochondrial ROS protection system, and this regulation was directly mediated by PGC-1 α . Moreover, analysis of tissues from eNOS $^{-/-}$ mice showed reduced levels of PGC-1 α and the mitochondrial ROS protection system, supporting the physiological relevance of the regulation (our unpublished results).

6. PATHOLOGIES

6.1. Neurodegenerative diseases

There is significant evidence that the pathogenesis of several neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, Friedreich's ataxia (FRDA), epileptic seizures, multiple sclerosis and amyotrophic lateral sclerosis, may involve the

generation of reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) associated with mitochondrial dysfunction. The mitochondrial genome may play an essential role in the pathogenesis of these diseases, and evidence of mitochondria as a site of damage in neurodegenerative disorders is based in part on observed decreases in the respiratory chain complex activities in Parkinson's, Alzheimer's, and Huntington's diseases. Such defects in respiratory complex activities, possibly associated with oxidant/antioxidant imbalance, are thought to underlie defects in energy metabolism and induce cellular degeneration.

Several factors have been suggested to explain the exacerbated sensitivity to mitochondrial dysfunction of the central nervous system (CNS). The CNS has a large potential oxidative capacity due to the high level of tissue O_2 consumption. However, the ability of brain to withstand oxidative stress is limited because of: a high content of easily oxidizable substrates, such as polyunsaturated fatty acids and catecholamines, a relatively low levels of antioxidants and antioxidant enzymes, the endogenous generation of ROS in specific reactions, the elevated content of iron in specific areas of the human brain (such as globus pallidus and substantia nigra) on top of the very little iron-binding capacity of the cerebrospinal fluid (low content of transferrin). Moreover, the CNS contains non-replicating neuronal cells which, once damaged, may be permanently dysfunctional or committed to apoptosis (163).

It is tempting to speculate that biochemical reactions based on free radical and reactive oxygen species play the pathogenetic role in all these neurodegenerative conditions, though it is yet undetermined what types of oxidative damage occur early in pathogenesis, and what types are secondary manifestations of the dying neurons. Delineation of the profile of oxidative damage in each disease will provide clues as to how the specific neuronal populations are differentially affected by individual disease conditions (164).

6.1.1. Parkinson's disease

Parkinson's disease is the second most prevalent neurological disorder, its major clinical manifestation are tremors in rest, bradykinesia, stiffness, and postural instability. Most patients also suffer cognitive problems. Pathologically it is characterized by the degeneration of the dopaminergic neurons located in the *substantia nigra pars compacta*, and the presence in the affected neurons of intracellular inclusions known as Lewy's bodies, which are made up of insoluble tangles of the protein α -synuclein. Although the symptomatic treatment has progressively improved in the last years, at present it is not possible to slow down or prevent the death of the dopaminergic neurons (165).

The etiology of the disease is still unknown, but accumulated evidence, both clinical and experimental, points out to the involvement of mitochondrial dysfunction and of oxidative stress. Mitochondria isolated from patients with Parkinson's disease shows a reduced activity in

complex I (NADH-ubiquinone reductase) and increased production of ROS. Decreased complex I activity was observed in the *substantia nigra* of postmortem samples obtained from patients with Parkinson's disease (166). These observations suggest that these alterations precede the clinical manifestations (167).

Exposure to environmental toxins that *in vitro* inhibit mitochondrial complex I activity, such as paraquat, MPTP and rotenone, have been associated with an increased risk to develop Parkinson's disease and have been used to establish animal models of the disease. Accordingly, dopaminergic neurons treated *in vitro* with complex I inhibitors show a reduction in electron transfer rates, lowered ATP levels and increased ROS production (168, 169).

The excessive ROS production has multiple effects that eventually result in cell death. Mitochondrial ROS hampers the process of synthesis and accumulation of dopamine in dopaminergic vesicles. As a consequence there is an accumulation of free 6-hydroxydopamine (6-HD), which behaves as a redox-cycling quinone in the presence of transition metals like Fe or Mn. This process serves to further exacerbate the production of ROS, and reduces the levels of dopamine. The neuron metabolism becomes glycolytic to compensate the mitochondrial defect, but excessive ROS finally block the glycolytic metabolism and result in apoptotic cell death. Increased lipid peroxidation is also observed, along with reduced glutathione levels, inhibition of the proteasome, and mutations in mtDNA, and at late stages in nDNA. The latter described effect seems to be responsible for the accumulation of alpha-synuclein in insoluble aggregates that are toxic to the cell. Neuronal cell death, and free dopamine activate the glia and initiate an inflammatory cascade that amplifies the damage (170-172).

6.1.2. Huntington's disease

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a pathological expansion of exonic CAG triplet repeats in the gene encoding the protein known as huntingtin (Htt) (173, 174). Disease symptomatology and progression are due to massive neuronal dysfunction and death in the striatum and in the cerebral cortex later in the disease. There is significant evidence that energy production is impaired in HD (175). Panov (176) found that mitochondria isolated from patients with HD had lower membrane potential than mitochondria from control subjects and upon calcium addition they depolarized faster than controls. These defects precede by months the onset of pathological or behavioral abnormalities. Additional evidence of the role of mitochondrial dysfunction in the disease comes from the observation that treatment of rodents or primates with 3-NP, an inhibitor of complex II and activator of the mitochondrial ATP-sensitive K channel (that regulates mitochondrial Ca^{2+} homeostasis) causes selective damage in the striatum that resembles the pathology and symptomatology of HD (177, 178). It seems that mutant Htt associates with mitochondrial membranes and somehow induces mitochondrial dysfunction through

inhibition of succinate oxidation (179, 180). Mutant huntingtin causes decreased mitochondrial oxidative phosphorylation and ATP production (181). What is the molecular target, is still a matter of controversy. Apparently, mitochondrial dysfunction becomes relevant when glycolysis is inhibited, a process that has also been described in Parkinson's disease patients (182), however it is not clear why glycolysis becomes deficient. Evidence for excessive ROS production and the role played by oxidative stress in the pathology is provided by the finding that the pathological deposits are immunoreactive to antibodies recognizing protein side-chains modified either directly by reactive oxygen or nitrogen species, or by products of lipid peroxidation or glycosylation. Although the source(s) of increased oxidative damage is not entirely clear, the findings of increased localization of redox-active transition metals in the brain regions most affected is consistent with their contribution to oxidative stress.

6.1.3. Alzheimer's disease

Alzheimer's disease (AD) is the most common form of dementia, and it is by definition characterized by the accumulation in the brain of extracellular neuritic plaques, together with the presence of intraneuronal neurofibrillary tangles (NFT) and progressive neurodegeneration. The plaques are composed of amyloid-beta, a peptide derived from the precursor protein (APP) (183).

Mitochondrial abnormalities, namely a decrease in mitochondrial mass and reduced mtDNA content, have been identified as a very early pathological sign in AD, preceding the appearance of NFT. The activity of key mitochondrial enzymes, mainly cytochrome oxidase is decreased in AD as well as mitochondrial membrane potential. Impaired complex IV activity has also been reported in Alzheimer's disease (184). The suggestion has been that AD results from the accumulation of mitochondrial mutations affecting mainly the complex IV. It has been suspected for many years that the pathogenesis involves oxidative stress, and it has been proposed that mitochondrial dysfunction may be a primary disorder in AD patients. Crucial supporting evidence comes from experiments showing that mitochondria isolated from the platelets of AD patients and introduced into a *rho*⁰ neuronal cell line by cell fusion showed increased rates of ROS generation and disturbed Ca^{2+} balance compared to control cybrids.

Significant increases in the levels of hemoxygenase-1 (HO-1) have been observed in AD brains in association with neurofibrillary tangles (185), and HO-1 mRNA was found to be increased in AD neocortex and cerebral vessels (183). HO-1 increase was not only detected in association with neurofibrillary tangles, but also co-localized with senile plaques and glial fibrillary acidic protein-positive astrocytes in AD brains (187). It has been proposed that the dramatic increase in HO-1 in AD may be a direct response to increased free heme associated with high levels of mitochondrial turnover. Removal of defective mitochondria would therefore induce HO-1 expression as an attempt to convert the highly damaging

heme into the antioxidants biliverdin and bilirubin. This process could explain the high levels of free Fe and Cu found in affected neurons. As previously mentioned free Fe^{2+} and Cu^{2+} catalyze the Fenton reaction that produces the highly reactive $\text{HO}^\cdot$ from H_2O_2 (188). The resulting damage facilitates the formation of beta-amyloid deposits (189).

Evidences for oxidative damage to proteins, DNA and increased lipid peroxidation have all been reported (190). Acrolein and HNE are increased in AD brain (191, 192), and HNE is covalently bound in excess to the glutamate transporter in AD (190). The latter finding, that could also be induced by addition of beta-amyloid to synaptosomes, coupled with the reported loss of glutamine synthetase activity in AD brain (190), suggest that glutamate-stimulated excitotoxic mechanisms could be important in the neurodegeneration in AD.

APP expression is induced in response to stress situations like hypoxia/ischemia. Therefore, it has been considered that APP could be a member of the cellular defense system to prevent neuronal death. However, accumulated beta-amyloid, forms Ca^{2+} channels that facilitate the massive entry of intracellular Ca^{2+} and the induction of apoptosis (194). Since the expression pattern of APP closely resembles that of heat shock proteins, HSPs have been intensely studied in brains of patients with Alzheimer's disease (195-199).

Local hypoxia due to vasculature malfunction and impaired microcirculation has been proposed as the origin of the mitochondrial dysfunction associated with advanced age. Risk factors like diabetes and hypercholesterolemia can induce mitochondrial dysfunction and oxidative stress in the vascular endothelial cells. The resulting endothelial degeneration would lead to a situation of local hypoxia or chronically impaired O_2 delivery to brain areas that will lead to mitochondrial oxidative stress in the glia, neurons and astrocytes (200).

6.1.4. Epilepsy

Epilepsies are a group of clinical syndromes that affect more than 50 million people worldwide. Epileptic seizures can be convulsive or nonconvulsive episodes characterized by synchronized abnormal electrical activity arising from a group of cerebral neurons. In contrast with genetic forms of epilepsy, acquired epilepsy accounts for a approximately 60% of all cases and is usually preceded by injury such as an episode of prolonged seizures or status epilepticus, febrile seizures, hypoxia, or trauma (201). These initial insults are thought to set in motion complex changes that result over time in the development of spontaneous recurring seizures. Neuronal death is considered by most the propagating factor being both the cause and the consequence of epileptic seizures. This idea is supported by the fact that surgical removal of damaged hippocampus improves the condition of epilepsy patients (202).

Evidence for mitochondrial dysfunction in epilepsy derives from the observed dramatic metabolic and bioenergetic changes that occur as consequence of both

acute seizure episodes and chronic epilepsy. In acute seizures there is a huge increase in glucose uptake, and glycolysis. However, the mitochondrial utilization of pyruvate is not increased, resulting in lactate buildup (203). During interstitial phases (between seizure episodes), hypometabolism is prevalent and associated with a low mitochondrial activity (204). These evidences have provided a basis for the management of epilepsies that can be treated by caloric restriction and/or a ketogenic diet (205). A prominent support of the role played by mitochondrial dysfunction in epilepsy comes from the occurrence of familiar epilepsy due to mutations in mtDNA or mutations in nuclear genes that alter mitochondrial function. Well characterized examples include, myoclonic epilepsy and ragged-red fiber disease (MERRF), due to a point mutation in mitochondrial tRNA Lys (206).

Although a precise role for ROS in epilepsies remains to be defined, a general role for ROS in seizure-induced neuronal death is supported by several observations: repeated seizures result in increased oxidation of cellular macromolecules, lipid peroxidation (207), and oxidative DNA damage (208).

The mitochondrial origin of ROS has been demonstrated in rats. Kainate-induced seizures inactivate O_2^- sensitive mitochondrial aconitase but not the cytosolic isoform, indicating mitochondria as the major site of seizure induced O_2^- production. The physiological relevance of mitochondrial ROS production is supported by the observation that in transgenic mice overexpressing Mn-SOD both aconitase inactivation and neuronal loss are attenuated (209), while both are exacerbated in mice partially deficient in Mn-SOD (210, 211). Mitochondrial production of O_2^- during seizures has also been demonstrated in an epilepsy rat model that is induced by lithium/pilocarpine (212, 213). Aconitase inactivation by O_2^- releases Fe^{2+} that reacts with H_2O_2 to produce $\text{OH}^\cdot$ (211).

A relevant role played by ROS in the disease has been demonstrated. Seizure-induced oxidative damage correlates with neuronal vulnerability, and oxidative damage occurs in areas that are vulnerable to kainate-induced damage. Also indicative is the observed strong age-dependency associated with neuronal damage (211). On the other hand, high levels of UCP-2 expression protect from seizure-induced ROS production (214). The central role of mitochondria is also supported by the observed activation of the mitochondrial apoptotic pathway (215, 216).

6.1.5. Friedreich ataxia (FRDA)

Friedreich ataxia (reviewed in (217)) is the commonest form of inherited ataxia. FRDA is an autosomal recessive degenerative disorder characterized by progressive gait and limb ataxia, loss of limb deep tendon reflexes, spasticity and extensor plantar responses (218). The causative mutation of FRDA is an abnormally expanded GAA triplet repeat in the first intron of the FRDA gene (219). Mutations in the FRDA gene, result in reduced expression of a protein called frataxin, which has

been shown to be localized in mitochondria (220). It is clearly established that frataxin in yeast plays an important role in the maintenance of mitochondrial iron homeostasis and cellular respiration. Deletion of the yeast frataxin homolog YFH1 results in a 10-fold increase in free iron within mitochondria along with increased ROS production, loss of mitochondrial DNA, and inability to carry out oxidative phosphorylation (221, 222). Further studies showed that frataxin deficiency leads to excessive free radical production in mitochondria and dysfunction of iron-sulfur cluster (ISC) containing enzymes (complexes I, II and III, and aconitase). Importantly, human frataxin complements YFH1, suggesting that frataxin function is conserved.

Loss of mitochondrial function and impaired oxidative phosphorylation, with severe deficiencies of mitochondrial respiratory chain complexes I and II/III and aconitase activities, have been observed in *post-mortem* samples from FRDA patients, associated with reduced levels of mitochondrial DNA and with increased iron deposition. Aconitase deficiency is suggestive that oxidative stress may induce a self-amplifying cycle of oxidative damage associated with mitochondrial dysfunction, which may also contribute to cellular toxicity and degeneration (223). There are also evidences of an impairment in vivo of glutathione homeostasis and antioxidant enzymes in patients with Friedreich's ataxia, suggesting a relevant role of free radical cytotoxicity in the pathophysiology of the disease. The precise sequence of events in FRDA is uncertain. However, impaired intramitochondrial metabolism associated, with increased free iron, and the consequent oxidative stress, are being considered as a possible pathogenic mechanism. Several model systems have been developed to understand the disease. Both decreased expression of frataxin protein (224), and selective inactivation in neuronal tissues are associated with neurological symptoms, mitochondrial iron-sulfur cluster-containing enzyme deficiencies and time-dependent mitochondrial iron accumulation (225).

Although the precise function of frataxin remains unknown, there is evidence to suggest that frataxin acts as a chaperone for Fe²⁺ and a storage compartment for excess iron (226), Fe-S cluster assembly (227), and prevention of oxidative stress. It also might detoxify ROS via activation of glutathione peroxidase and elevation of thiols (228). An early step of ISC synthesis, which takes place on the scaffold protein Isu1, is greatly enhanced by frataxin. It has been proposed that frataxin directly binds iron, shielding it from H₂O₂ and making it available for ISC synthesis. It is unclear whether this postulated chaperone function is specific to ISC synthesis. Yeast data indicate that heme synthesis may also be stimulated by frataxin, suggesting a frataxin more general role in mitochondrial iron handling. Alternative hypotheses view frataxin as a stabilizer of a complex including Isu1 and the nascent ISC, as a protein with a primarily antioxidant function, and as an activator of the respiratory chain.

6.2. Cancer and ageing

6.2.1. Cancer

Even though there is a large body of literature linking free radicals and antioxidant enzymes to cancer,

most of the evidence is correlative, (*i.e.* cancer cells are nearly always low in Mn-SOD and catalase activity (229)). Evidence for a causal relationship is that in various model systems, ROS cause cancer (230). Moreover, antioxidants in general, and SOD and SOD-mimetics in particular, inhibit malignant transformation. Molecular biology techniques have been used to show a role for SOD in transformation. Over-expression of Mn-SOD by cDNA transfection leads to inhibition of radiation-induced transformation in mouse fibroblasts (231), and over-expression of Mn-SOD in several cancer cell lines led to suppression of cell growth. Mn-SOD in combination with chemicals that inhibit H₂O₂ removal causes cell killing of cancer cells by H₂O₂ toxicity. Moreover, Mn-SOD suppresses tumor metastasis (232). On the other hand, life-long reduction in Mn-SOD activity (in heterozygotic *sod2*^{+/-} mice) results in a much higher incidence of cancer (233),

The origin of cancer is multifactorial, the best characterized carcinogens are those that damage DNA directly, followed by those that directly alter mitosis (*i.e.* those that modify the structure of microtubules). However, the relevance of carcinogens whose main action is the increased production of ROS, is becoming evident (234, 235). ROS can mutate DNA both directly and indirectly. Free radicals, capable of both directly damaging DNA and affecting the DNA repair machinery, enhance genetic instability of affected cells, thus contributing to the first stage of neoplastic transformation also known as "initiation". The activation of pro-inflammatory factors like NFκB and AP-1 contribute to the setting of a oxidative stress situations, and deregulation of the machinery that controls cellular proliferation. In fact chronic inflammation has long been suggested to constitute a risk factor for a variety of epithelial cancers such as malignancies of prostate, cervix, esophagus, stomach, liver, colon, pancreas, and bladder. The inflammatory response is typically accompanied by an increased generation of free radicals and an increased production of cytokines, chemokines, growth factors and angiogenic factors. Cytokines and growth factors can further promote tumor growth by stimulating cell proliferation, adhesion, vascularization, and metastatic potential of later stage tumors. (236). ROS may have a multifactorial origin, mitochondria being one of the possible sources. Arsenic, a well characterized and common carcinogen, damages mitochondria and promotes mitochondrial ROS production (237, 238), and the carcinogen benzo(a)pyrene induces mitochondrial dysfunction (239). Importantly, the accumulation of mutations in people not exposed to carcinogens is associated with the presence of peroxidized lipids. Ultra sensitive methods for measuring DNA adducts allow the quantification and elucidation of DNA damage arising from oxidative stress and lipid peroxidation, which have been found to be the driving forces in several human malignancies. DNA damage in unexposed individuals has been shown unequivocally due to lipid peroxidation products (240). The accumulation of lipid peroxidation products is a normal consequence of mitochondrial dysfunction and ROS production in subjects with hyperlipidemia and/or hyperglycemia.

A number of studies have reported a high incidence of mtDNA mutations in cancer cells implicating these mutations in the process of carcinogenesis (241). Mitochondrial genomic aberrations have been reported in solid tumors of the breast, colon, stomach, liver, kidney, bladder, head/neck, and lung. Alterations in the expression of mtDNA transcripts in a variety of cancer types are also well described. In solid tumors, the observed elevated expression of mtDNA-genes coding for subunits of the mitochondrial electron respiratory chain may reflect mitochondrial adaptation to perturbations in cellular energy requirements (242). Mitochondrial DNA mutations can initiate a cascade of events leading to a continuous increase in the production of reactive oxygen species (persistent oxidative stress), a condition that probably favors tumor formation.

In general, cancer cells show an elevated production of mitochondrial ROS and a low metabolic capacity (243), associated to an exacerbated sensibility to ROS and inhibitors of mitochondrial functions (244). Therefore, the generation of ROS could be exploited therapeutically in the treatment of cancer. One of the first developed drugs that generate ROS was procarbazine, that is readily oxidized to its azo derivative generating ROS. Forty years ago, Berneis reported a synergistic effect in DNA degradation when procarbazine was combined with radiation; this was confirmed in preclinical *in vivo* models. Early uncontrolled clinical trials suggested an enhancement of the radiation effect with procarbazine, but two randomized trials failed to confirm this. The role of ROS in cancer treatments and in the development of chemotherapy resistance is now better understood. The possibility of exploiting drugs that by redox cycling generate O_2^- and H_2O_2 or other ROS as cancer treatment is re-emerging as a promising therapeutic option with the development of agents such as buthionine sulfoximine and motexafin gadolinium (245).

6.2.2. Aging

Harman in 1972 first proposed that mitochondria may have a central role in the process of ageing. According to this theory, free radicals generated through mitochondrial metabolism can act as causative factor of abnormal function and cell death. Mitochondria are the cellular most significant source of oxidants and *in vitro* studies have indicated that approximately 1-2% of electron flow through the electron transfer chain results in the generation of O_2^- . Moreover, various toxins in the environment can injure mitochondrial enzymes, leading to increased generation of free radicals that over the lifespan would eventually play a role in aging (246, 247).

Mitochondrial generation of ROS is a major cause of cellular damage that accumulates over time and seems responsible for aging (248). During aging some of the free radical scavenging systems are decreased (249, 250) and as a consequence an increased escape of free radicals occurs, targeting lipids, proteins and DNA in proximity to the respiratory chain (251). Oxidized lipids decrease the fluidity and increase the permeability of the inner mitochondrial membrane (252). Oxidative damage

proteins also increase markedly with age (249). Toxic roles for oxidized proteins have been proposed (*i.e.* Alzheimer's disease). Furthermore, levels of the oxidized nucleotide 8-hydroxy-deoxyguanosine (8-OH-dG), a biomarker of DNA damage has been show to increase in aging. In high metabolic tissues like brain and muscle, levels of 8-OH-dG in mtDNA exceed that of nuclear DNA nDNA some 16-fold (254). Finally, several age-related disorders (Parkinson, Alzheimer, etc.) have been shown to be linked to higher levels of mtDNA mutations than the age-matched controls (241, 255).

The levels of cardiolipin, an acidic phospholipid that occurs only in mitochondrial inner membrane, decrease with age. Cardiolipin is involved in protein translocation and has electrical insulating properties, contributing to the maintenance of transmembrane potential (256). Typically, mitochondria from aged subjects have decreased membrane potential (257), reduced cytochrome *c* levels (258), and are larger and less numerous. They also show vacuolization, cristae rupture and accumulation of paracrystalline inclusions, indicating that mitochondrial function is severely impaired (259, 260).

6.3. Diabetes, atherosclerosis and ischemia reperfusion injury

6.3.1. Diabetes

It is well established that mitochondrial function is required for normal glucose-stimulated insulin secretion from pancreatic beta cells. Several lines of evidence indicate that insulin resistance is an early feature of type 2 diabetes. As skeletal muscle and liver become more and more insulin resistant, beta cell production of insulin increases. When type 2 diabetes develops beta cells do not secrete enough insulin to compensate for the increased demand.

Beta cell dysfunction can be directly associated with a reduced mitochondrial function, as evidenced by the observation that increased UCP-2 levels that impair mitochondrial ATP synthesis also prevent insulin secretion (261). Both elevated glucose levels (262) and high concentration of triglycerides in plasma (263) that are important risk factors for type 2 diabetes have been proposed to be responsible for mitochondrial dysfunction, reduced ATP synthesis and elevated ROS levels in beta cells. A recent study demonstrates that hyperglycemia-induced mitochondrial O_2^- production activates uncoupling protein 2, which decreases the ATP/ADP ratio and thus reduces the insulin-secretory response. These data suggest that pharmacologic inhibition of mitochondrial O_2^- overproduction in beta cells exposed to hyperglycemia could prevent a positive feed-forward loop of glucotoxicity that drives impaired glucose tolerance toward frank type 2 diabetes (264).

6.3.2. Atherosclerosis

In atherothrombosis, ROS are responsible for the initiation and perpetuation of the pathological process. Each of the known risk factors for atherothrombosis promotes vascular oxidant stress, including hypercholesterolemia, hyperglycemia, hypertension, diabetes mellitus, tobacco use and hyperhomocysteinemia. Under normal circumstances, endothelial cells provide a permeability barrier to blood cells

and macromolecules, maintaining the relaxed state of the blood vessel, with limited affinity for circulating leucocytes, suppressing VSMC migration and maintaining a local antithrombotic environment. Upon exposure to risk factors, the phenotype of the endothelial cells changes. It becomes permeable to blood cells and macromolecules, is avid for leucocytes, promotes VSMC migration and proliferation and supports thrombotic responses. Endothelial dysfunction is associated with a loss of the normal bioactivity of NO. This decrease in NO bioactivity is a consequence of decreased production by eNOS, increased oxidative inactivation of NO by O₂⁻, or both (265, 266).

The initiation of the atherosclerosis processes is due in part to the deposition of oxidized lipids, like cholesterol, in the vascular wall. It seems that the clearance rate of oxidized cholesterol and other oxidized lipids is much slower than that of normal cholesterol. The oxidation of lipids takes place because of the excessive production of ROS in the endothelium. The initial endothelial dysfunction can be attributable to the mitochondrial production of ROS in the case of hyperglycemia, it has been shown that elevated glucose levels impair mitochondrial function and induce the production of mitochondrial ROS by complex II (267).

6.3.3. Ischemia reperfusion injury

Perhaps it seems self-evident that, if cells are deprived of glucose and oxygen, they will eventually die. In stroke and in cardiac infarct, this clearly defines cell death in the short term. However, there is a prevalent strange phenomenon, which is that cells that have been able to withstand a period of ischemia paradoxically die when they are reperfused. This has been called reperfusion injury or the oxygen paradox. Although the mechanism has not been fully elucidated, it seems likely that, as mitochondrial respiration is inhibited and ATP gradually falls, anaerobic glycolysis generates intracellular acidosis. The acidification drives the entry of Ca²⁺ into the cell. At reperfusion the mitochondrial potential abruptly recovers at a time when cytosolic Ca²⁺ is high, mitochondria will therefore become overloaded with Ca²⁺. Simultaneously, the abrupt return to respiration will be accompanied by a burst of mitochondrial free radical generation. The combination of high mitochondrial calcium and oxidative stress with low ATP levels and high Pi provides the setting for the opening of the permeability transition pore, collapse of membrane potential and induction of apoptosis (268, 269).

7. CONCLUSIONS AND PERSPECTIVES

Although it has long been established the fundamental role that mitochondria play to sustain aerobic life, it is but recently that it has emerged the notion that mitochondrial dysfunction is at the core of a vast array of major human pathologies. The final general conclusion is if anything surprisingly simple, sick mitochondria means sick bodies and the most affected tissues are those that either have high metabolic rates, like skeletal muscle, heart, and neurons, or are particularly sensitive to changing metabolic conditions such as beta-cells or vascular endothelial cells. But, why do mitochondria get sick? The answer is again

appalling self evident, it can be due to metabolic overload (high levels of glucose or lipids, metabolic syndrome), to the direct action of toxic chemicals on the mitochondria, like rotenone, or to mutations in certain genes.

However, there is still a long way to go in order to understand how the mechanism that protect mitochondria from oxidative stress work and are regulated, and this knowledge is fundamental to be able to develop new therapies. Until then, the best way to go is to follow the advice of your physician, have a healthy diet and exercise regularly.

8. ACKNOWLEDGEMENTS

This work was supported by an institutional grant from the CNIC, by Plan Nacional de I+D+I grants SAF2003-01039 and SAF2003-04901 and grant-in-aid from the Spanish Society of Nephrology to Dr. Santiago Lamas. Sara Borniquel is holder of grant SAF2003-04901 predoctoral fellowship. Inmaculada Valle is holder of a CNIC-Bancaja predoctoral fellowship. Maria Monsalve is holder of a Ramon y Cajal contract from the Ministerio de Educación y Ciencia.

9. REFERENCES

1. Brand M D, C. Affourtit, T. C. Esteves, K. Green, A. J. Lambert, S. Miwa, J. L. Pakay & N. Parker: Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. *Free Radic Biol Med* 37, 755-767 (2004)
2. Scarpulla R C: Nuclear activators and coactivators in mammalian mitochondrial biogenesis. *Biochim Biophys Acta* 1576, 1-14 (2002)
3. Duchon M R: Mitochondria in health and disease: perspectives on a new mitochondrial biology. *Mol Aspects Med* 25, 365-451 (2004)
4. Wallace D C: Mitochondrial diseases in man and mouse. *Science* 283, 1482-1488 (1999)
5. Finsterer J: Mitochondriopathies. *Eur J Neurol* 11, 163-186 (2004)
6. Nordberg J & E. S. Arner: Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. *Free Radic Biol Med* 31, 1287-1312 (2001)
7. Li Y, T. T. Huang, E. J. Carlson, S. Melov, P. C. Ursell, J. L. Olson, L. J. Noble, M. P. Yoshimura, C. Berger, P. H. Chan, D. C. Wallace & C. J. Epstein: Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. *Nat Genet* 11, 376-381 (1995)
8. Chen Z, B. Siu, Y. S. Ho, R. Vincent, C. C. Chua, R. C. Hamdy & B. H. Chua: Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice. *J Mol Cell Cardiol* 30, 2281-2289 (1998)
9. Chen H, X. Li & P. N. Epstein MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. *Diabetes* 54, 1437-1446 (2005)
10. Callio J, T. D. Oury & C. T. Chu: Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. *J Biol Chem* 280, 18536-18542 (2005)

11. Ho Y S, R. Vincent, M. S. Dey, J. W. Slot & J. D. Crapo: Transgenic models for the study of lung antioxidant defense: enhanced manganese-containing superoxide dismutase activity gives partial protection to B6C3 hybrid mice exposed to hyperoxia. *Am J Respir Cell Mol Biol* 18, 538-547 (1998)
12. Goth L, P. Rass & A. Pay: Catalase enzyme mutations and their association with diseases. *Mol Diagn* 8, 141-149 (2004)
13. Ho Y S, Y. Xiong, W. Ma, A. Spector & D. S. Ho: Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury. *J Biol Chem* 279, 32804-32812 (2004)
14. Ho Y S, J. L. Magnenat, M. Gargano & J. Cao: The nature of antioxidant defense mechanisms: a lesson from transgenic studies. *Environ Health Perspect* 106 Suppl 5, 1219-1228 (1998)
15. Yang H, L. J. Roberts, M. J. Shi, L. C. Zhou, B. R. Ballard, A. Richardson & Z. M. Guo: Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein. *E Circ Res* 95, 1075-1081 (2004)
16. Shi M, H. Yang, E. D. Motley & Z. Guo: Overexpression of Cu/Zn-superoxide dismutase and/or catalase in mice inhibits aorta smooth muscle cell proliferation. *Am J Hypertens* 17, 450-456 (2004)
17. Schriener S E, N. J. Linford, G. M. Martin, P. Treuting, C. E. Ogburn, M. Emond, P. E. Coskun, W. Ladiges, N. Wolf, H. Van Remmen, D. C. Wallace & P. S. Rabinovitch: Extension of murine life span by overexpression of catalase targeted to mitochondria. *Science* 308, 1909-1911 (2005)
18. Watabe S, T. Hiroi, Y. Yamamoto, Y. Fujioka, H. Hasegawa, N. Yago & S. Y. Takahashi: SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria. *Eur J Biochem* 249, 52-60 (1997)
19. Araki M, H. Nanri, K. Ejima, Y. Murasato, T. Fujiwara, Y. Nakashima & M. Ikeda: Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. *J Biol Chem* 274, 2271-2278 (1999)
20. Seo M S, S. W. Kang, K. Kim, I. C. Baines, T. H. Lee & S. G. Rhee: Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. *J Biol Chem* 275, 20346-20354 (2000)
21. Zhou Y, K. H. Kok, A. C. Chun, C. M. Wong, H. W. Wu, M. C. Lin, P. C. Fung, H. Kung & D. Y. Jin: Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis. *Biochem Biophys Res Commun* 268, 921-927 (2000)
22. Banmeyer I, C. Marchand, A. Clippe & B. Knoop: Human mitochondrial peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen peroxide. *FEBS Lett* 579, 2327-2333 (2005)
23. Banmeyer I, C. Marchand, C. Verhaeghe, B. Vucic, J. F. Rees & B. Knoop: Overexpression of human peroxiredoxin 5 in subcellular compartments of Chinese hamster ovary cells: effects on cytotoxicity and DNA damage caused by peroxides. *Free Radic Biol Med* 36, 65-77 (2004)
24. Tien Nguyen-nhu N & B. Knoop: Mitochondrial and cytosolic expression of human peroxiredoxin 5 in *Saccharomyces cerevisiae* protect yeast cells from oxidative stress induced by paraquat. *FEBS Lett* 544, 148-152 (2003)
25. Kinnula V L, S. Lehtonen, R. Sormunen, R. Kaarteenaho-Wiik, S. W. Kang, S. G. Rhee & Y. Soini: Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. *J Pathol* 196, 316-323 (2002)
26. Choi J H, T. N. Kim, S. Kim, S. H. Baek, J. H. Kim, S. R. Lee & J. R. Kim: Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. *Anticancer Res* 22, 3331-3335 (2002)
27. Noh D Y, S. J. Ahn, R. A. Lee, S. W. Kim, I. A. Park & H. Z. Chae: Overexpression of peroxiredoxin in human breast cancer. *Anticancer Res* 21, 2085-2090 (2001)
28. Karihtala P, A. Mantyniemi, S. W. Kang, V. L. Kinnula & Y. Soini: Peroxiredoxins in breast carcinoma. *Clin Cancer Res* 9, 3418-3424 (2003)
29. Chang T S, C. S. Cho, S. Park, S. Yu, S. W. Kang & S. G. Rhee: Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. *J Biol Chem* 279, 41975-41984 (2004)
30. Nonn L, M. Berggren & G. Powis: Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. *Mol Cancer Res* 1, 682-689 (2003)
31. Chandel N S, E. Maltepe, E. Goldwasser, C. E. Mathieu, M. C. Simon & P. T. Schumacker: Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. *Proc Natl Acad Sci U S A* 95, 11715-11720 (1998)
32. Chae H Z, S. W. Kang & S. G. Rhee: Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. *Methods Enzymol* 300, 219-226 (1999)
33. Miranda-Vizuet A, A. E. Damdimopoulos, J. R. Pedrajas, J. A. Gustafsson & G. Spyrou: Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. *Eur J Biochem* 261, 405-412 (1999)
34. Spyrou G, E. Enmark, A. Miranda-Vizuet & J. Gustafsson: Cloning and expression of a novel mammalian thioredoxin. *J Biol Chem* 272, 2936-2941 (1997)
35. Miranda-Vizuet A, A. E. Damdimopoulos & G. Spyrou: The mitochondrial thioredoxin system. *Antioxid Redox Signal* 2, 801-810 (2000)
36. Damdimopoulos A E, A. Miranda-Vizuet, M. Peltto-Huikko, J. A. Gustafsson & G. Spyrou: Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. *J Biol Chem* 277, 33249-33257 (2002)
37. Chen Y, J. Cai, T. J. Murphy & D. P. Jones: Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. *J Biol Chem* 277, 33242-33248 (2002)
38. Nonn L, R. R. Williams, R. P. Erickson & G. Powis: The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. *Mol Cell Biol* 23, 916-922 (2003)
39. Tanaka T, F. Hosoi, Y. Yamaguchi-Iwai, H. Nakamura, H. Masutani, S. Ueda, A. Nishiyama, S. Takeda, H. Wada,

- G. Spyrou & J. Yodoi: Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. *Embo J* 21, 1695-1703 (2002)
40. Chiueh C C, T. Andoh & P. B. Chock: Induction of thioredoxin and mitochondrial survival proteins mediates preconditioning-induced cardioprotection and neuroprotection. *Ann N Y Acad Sci* 1042, 403-418 (2005)
41. Stroeve S A, T. S. Gluschenko, E. I. Tjulkova, G. Spyrou, E. A. Rybnikova, M. O. Samoilov & M. Pelto-Huikko: Preconditioning enhances the expression of mitochondrial antioxidant thioredoxin-2 in the forebrain of rats exposed to severe hypobaric hypoxia. *J Neurosci Res* 78, 563-569 (2004)
42. Rabilloud T, M. Heller, M. P. Rigobello, A. Bindoli, R. Aebersold & J. Lunardi: The mitochondrial antioxidant defence system and its response to oxidative stress. *Proteomics* 1, 1105-1110 (2001)
43. Lee S R, J. R. Kim, K. S. Kwon, H. W. Yoon, R. L. Levine, A. Ginsburg & S. G. Rhee: Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. *J Biol Chem* 274, 4722-4734 (1999)
44. Gasdaska P Y, M. M. Berggren, M. J. Berry & G. Powis: Cloning, sequencing and functional expression of a novel human thioredoxin reductase. *FEBS Lett* 442, 105-111 (1999)
45. Conrad M, C. Jakupoglu, S. G. Moreno, S. Lippl, A. Banjac, M. Schneider, H. Beck, A. K. Hatzopoulos, U. Just, F. Sinowatz, W. Schmahl, K. R. Chien, W. Wurst, G. W. Bornkamm & M. Brielmeier: Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. *Mol Cell Biol* 24, 9414-9423 (2004)
46. Kim M R, H. S. Chang, B. H. Kim, S. Kim, S. H. Baek, J. H. Kim, S. R. Lee & J. R. Kim: Involvements of mitochondrial thioredoxin reductase (TrxR2) in cell proliferation. *Biochem Biophys Res Commun* 304, 119-124 (2003)
47. Hammond C L, T. K. Lee & N. Ballatori: Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. *J Hepatol* 34, 946-954 (2001)
48. Fernandez-Checa J C, C. Garcia-Ruiz, A. Colell, A. Morales, M. Mari, M. Miranda & E. Ardite: Oxidative stress: role of mitochondria and protection by glutathione. *Biofactors* 8, 7-11 (1998)
49. Boyd-Kimball D, R. Sultana, H. M. Abdul & D. A. Butterfield: Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. *J Neurosci Res* 79, 700-706 (2005)
50. Cardoso S M & C. R. Oliveira: Glutathione cycle impairment mediates A beta-induced cell toxicity. *Free Radic Res* 37, 241-250 (2003)
51. Coppola S & L. Ghibelli: GSH extrusion and the mitochondrial pathway of apoptotic signalling. *Biochem Soc Trans* 28, 56-61 (2000)
52. Gladyshev V N, A. Liu, S. V. Novoselov, K. Krysan, Q. A. Sun, V. M. Kryukov, G. V. Kryukov & M. F. Lou: Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2. *J Biol Chem* 276, 30374-30380 (2001)
53. Beer S M, E. R. Taylor, S. E. Brown, C. C. Dahm, N. J. Costa, M. J. Runswick & M. P. Murphy: Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: implications for mitochondrial redox regulation and antioxidant defense. *J Biol Chem* 279, 47939-47951 (2004)
54. Enoksson M, A. P. Fernandes, S. Prast, C. H. Lillig, A. Holmgren & S. Orrenius: Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. *Biochem Biophys Res Commun* 327, 774-779 (2005)
55. Lillig C H, C. Berndt, O. Vergnolle, M. E. Lonn, C. Hudemann, E. Bill & A. Holmgren: Characterization of human glutaredoxin 2 as iron-sulfur protein: a possible role as redox sensor. *Proc Natl Acad Sci U S A* 102, 8168-8173 (2005)
56. Kelner M J & M. A. Montoya: Structural organization of the human glutathione reductase gene: determination of correct cDNA sequence and identification of a mitochondrial leader sequence. *Biochem Biophys Res Commun* 269, 366-368 (2000)
57. Nakagawa Y: Role of mitochondrial phospholipid hydroperoxide glutathione peroxidase (PHGPx) as an antiapoptotic factor. *Biol Pharm Bull* 27, 956-960 (2004)
58. Knopp E A, T. L. Arndt, K. L. Eng, M. Caldwell, R. C. LeBoeuf, S. S. Deeb & K. D. O'Brien: Murine phospholipid hydroperoxide glutathione peroxidase: cDNA sequence, tissue expression, and mapping. *Mamm Genome* 10, 601-605 (1999)
59. Imai H & Y. Nakagawa: Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. *Free Radic Biol Med* 34, 145-169 (2003)
60. Imai H, F. Hirao, T. Sakamoto, K. Sekine, Y. Mizukura, M. Saito, T. Kitamoto, M. Hayasaka, K. Hanaoka & Y. Nakagawa: Early embryonic lethality caused by targeted disruption of the mouse PHGPx gene. *Biochem Biophys Res Commun* 305, 278-286 (2003)
61. Sakamoto H, T. Tosaki & Y. Nakagawa: Overexpression of phospholipid hydroperoxide glutathione peroxidase modulates acetyl-CoA, 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase activity. *J Biol Chem* 277, 50431-50438 (2002)
62. Ran Q, H. Liang, M. Gu, W. Qi, C. A. Walter, L. J. Roberts, 2nd, B. Herman, A. Richardson & H. Van Remmen: Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. *J Biol Chem* 279, 55137-55146 (2004)
63. Hollander J M, K. M. Lin, B. T. Scott & W. H. Dillmann: Overexpression of PHGPx and HSP60/10 protects against ischemia/reoxygenation injury. *Free Radic Biol Med* 35, 742-751 (2003)
64. Schrauwen P & M. Hesselink: UCP2 and UCP3 in muscle controlling body metabolism. *J Exp Biol* 205, 2275-2285 (2002)
65. Pecqueur C, M. C. Alves-Guerra, C. Gelly, C. Levi-Meyrueis, E. Couplan, S. Collins, D. Ricquier, F. Bouillaud & B. Miroux: Uncoupling protein 2, in vivo distribution, induction upon oxidative stress, and evidence for translational regulation. *J Biol Chem* 276, 8705-8712 (2001)
66. Cortez-Pinto H, H. Zhi Lin, S. Qi Yang, S. Odwin Da Costa & A. M. Diehl: Lipids up-regulate uncoupling

- protein 2 expression in rat hepatocytes. *Gastroenterology* 116, 1184-1193 (1999)
67. Rashid A, T. C. Wu, C. C. Huang, C. H. Chen, H. Z. Lin, S. Q. Yang, F. Y. Lee & A. M. Diehl: Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. *Hepatology* 29, 1131-1138 (1999)
68. Chavin K D, S. Yang, H. Z. Lin, J. Chatham, V. P. Chacko, J. B. Hoek, E. Walajtys-Rode, A. Rashid, C. H. Chen, C. C. Huang, T. C. Wu, M. D. Lane & A. M. Diehl: Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. *J Biol Chem* 274, 5692-5700 (1999)
69. Li B, J. O. Holloszy & C. F. Semenkovich: Respiratory uncoupling induces delta-aminolevulinate synthase expression through a nuclear respiratory factor-1-dependent mechanism in HeLa cells. *J Biol Chem* 274, 17534-17540 (1999)
70. Arsenijevic D, H. Onuma, C. Pecqueur, S. Raimbault, B. S. Manning, B. Miroux, E. Couplan, M. C. Alves-Guerra, M. Goubern, R. Surwit, F. Bouillaud, D. Richard, S. Collins & D. Ricquier :Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. *Nat Genet* 26, 435-439 (2000)
71. Blanc J, M. C. Alves-Guerra, B. Esposito, S. Rousset, P. Gourdy, D. Ricquier, A. Tedgui, B. Miroux & Z. Mallat: Protective role of uncoupling protein 2 in atherosclerosis. *Circulation* 107, 388-390 (2003)
72. Chan C B, M. C. Saleh, V. Koshkin & M. B. Wheeler :Uncoupling protein 2 and islet function *Diabetes* 53 Suppl 1, S136-142 (2004)
73. Teshima Y, M. Akao, S. P. Jones & E. Marban: Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. *Circ Res* 93, 192-200 (2003)
74. Li L X, F. Skorpen, K. Egeberg, I. H. Jorgensen & V. Grill: Uncoupling protein-2 participates in cellular defense against oxidative stress in clonal beta-cells. *Biochem Biophys Res Commun* 282, 273-277 (2001)
75. Horvath T L, S. Diano & C. Barnstable: Mitochondrial uncoupling protein 2 in the central nervous system: neuromodulator and neuroprotector. *Biochem Pharmacol* 65, 1917-1921 (2003)
76. Diano S, R. T. Matthews, P. Patrylo, L. Yang, M. F. Beal, C. J. Barnstable & T. L. Horvath: Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. *Endocrinology* 144, 5014-5021 (2003)
77. Bechmann I, S. Diano, C. H. Warden, T. Bartfai, R. Nitsch & T. L. Horvath: Brain mitochondrial uncoupling protein 2 (UCP2): a protective stress signal in neuronal injury. *Biochem Pharmacol* 64, 363-367 (2002)
78. Conti B, S. Sugama, J. Lucero, R. Winsky-Sommerer, S. A. Wirz, P. Maher, Z. Andrews, A. M. Barr, M. C. Morale, C. Paneda, J. Pemberton, S. Gaidarova, M. M. Behrens, F. Beal, P. P. Sanna, T. Horvath & T. Bartfai: Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-tetrahydropyridine toxicity. *J Neurochem* 93, 493-501 (2005)
79. Calabrese V, G. Scapagnini, C. Colombrita, A. Ravagna, G. Pennisi, A. M. Giuffrida Stella, F. Galli & D. A. Butterfield: Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. *Amino Acids* 25, 437-444 (2003)
80. Sammut I A & J. C. Harrison: Cardiac mitochondrial complex activity is enhanced by heat shock proteins. *Clin Exp Pharmacol Physiol* 30, 110-115 (2003)
81. Morimoto R I, P. E. Kroeger & J. J. Cotto: The transcriptional regulation of heat shock genes: a plethora of heat shock factors and regulatory conditions. *Exs* 77, 139-163 (1996)
82. Voellmy R: On mechanisms that control heat shock transcription factor activity in metazoan cells. *Cell Stress Chaperones* 9, 122-133 (2004)
83. Mathew A, Y. Shi, C. Jolly & R. I. Morimoto: Analysis of the mammalian heat-shock response. Inducible gene expression and heat-shock factor activity. *Methods Mol Biol* 99, 217-255 (2000)
84. Christians E S, L. J. Yan & I. J. Benjamin: Heat shock factor 1 and heat shock proteins: critical partners in protection against acute cell injury. *Crit Care Med* 30, S43-50 (2002)
85. Cotto J J & R. I. Morimoto: Stress-induced activation of the heat-shock response: cell and molecular biology of heat-shock factors. *Biochem Soc Symp* 64, 105-118 (1999)
86. Tavaría M, T. Gabriele, I. Kola & R. L. Anderson: A hitchhiker's guide to the human Hsp70 family. *Cell Stress Chaperones* 1, 23-28 (1996)
87. Barrett M J, V. Alones, K. X. Wang, L. Phan & R. H. Swerdlow: Mitochondria-derived oxidative stress induces a heat shock protein response. *J Neurosci Res* 78, 420-429 (2004)
88. Ostermann J, A. L. Horwich, W. Neupert & F. U. Hartl: Protein folding in mitochondria requires complex formation with hsp60 and ATP hydrolysis. *Nature* 341, 125-130 (1989)
89. Cabisco E, G. Belli, J. Tamarit, P. Echave, E. Herrero & J. Ros: Mitochondrial Hsp60, resistance to oxidative stress, and the labile iron pool are closely connected in *Saccharomyces cerevisiae*. *J Biol Chem* 277, 44531-44538 (2002)
90. Wadhwa R, K. Taira & S. C. Kaul: An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? *Cell Stress Chaperones* 7, 309-316 (2002)
91. Liu Y, W. Liu, X. D. Song & J. Zuo: Effect of GRP75/mthsp70/PBP74/mortalin overexpression on intracellular ATP level, mitochondrial membrane potential and ROS accumulation following glucose deprivation in PC12 cells. *Mol Cell Biochem* 268, 45-51 (2005)
92. Hohfeld J & F. U. Hartl: Role of the chaperonin cofactor Hsp10 in protein folding and sorting in yeast mitochondria. *J Cell Biol* 126, 305-315 (1994)
93. Lin K M, B. Lin, I. Y. Lian, R. Mestrl, I. E. Scheffler & W. H. Dillmann: Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemia-reoxygenation. *Circulation* 103, 1787-1792 (2001)
94. Liu Q, J. Krzewska, K. Liberek & E. A. Craig: Mitochondrial Hsp70 Ssc1: role in protein folding. *J Biol Chem* 276, 6112-6118 (2001)
95. Sighting M, D. Mokranjac, A. Azem, W. Neupert & K. Hell: Maintenance of structure and function of

mitochondrial Hsp70 chaperones requires the chaperone Hsp1. *Embo J* 24, 1046-1056 (2005)

96. Maines M & D.Gibbs: P. E. 30 some years of heme oxygenase: from a "molecular wrecking ball" to a "mesmerizing" trigger of cellular events. *Biochem Biophys Res Commun* 338, 568-577 (2005)

97. Liu H, R. Colavitti, I. I. Rovira & T. Finkel: Redox-Dependent Transcriptional Regulation. *Circ Res* 97, 967-974 (2005)

98. Favreau L V & C. B. Pickett: The rat quinone reductase antioxidant response element. Identification of the nucleotide sequence required for basal and inducible activity and detection of antioxidant response element-binding proteins in hepatoma and non-hepatoma cell lines. *J Biol Chem* 270, 24468-24474 (1995)

99. Dalton T P, H. G. Shertzer & A. Puga: Regulation of gene expression by reactive oxygen. *Annu Rev Pharmacol Toxicol* 39, 67-101 (1999)

100. Motohashi H, T. O'Connor, F. Katsuoka, J. D. Engel & M. Yamamoto: Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. *Gene* 294, 1-12 (2002)

101. Venugopal R & A. K. Jaiswal: Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. *Proc Natl Acad Sci U S A* 93, 14960-14965 (1996)

102. Kwong M, Y. W. Kan & J. Y. Chan: The CNC basic leucine zipper factor, Nrf1, is essential for cell survival in response to oxidative stress-inducing agents. Role for Nrf1 in gamma-gcs(l) and gss expression in mouse fibroblasts. *J Biol Chem* 274, 37491-37498 (1999)

103. Chan K & Y. W. Kan: Nrf2 is essential for protection against acute pulmonary injury in mice. *Proc Natl Acad Sci U S A* 96, 12731-12736 (1999)

104. Ishii T, K. Itoh, S. Takahashi, H. Sato, T. Yanagawa, Y. Katoh, S. Bannai & M. Yamamoto: Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. *J Biol Chem* 275, 16023-16029 (2000)

105. Leung L, M. Kwong, S. Hou, C. Lee & J. Y. Chan: Deficiency of the Nrf1 and Nrf2 transcription factors results in early embryonic lethality and severe oxidative stress. *J Biol Chem* 278, 48021-48029 (2003)

106. Jaiswal A K: Regulation of antioxidant response element-dependent induction of detoxifying enzyme synthesis. *Methods Enzymol* 378, 221-238 (2004)

107. Borrello S & B. Dimple: NF kappa B-independent transcriptional induction of the human manganous superoxide dismutase gene. *Arch Biochem Biophys* 348, 289-294 (1997)

108. Kiningham K K & D. K. St Clair: Overexpression of manganese superoxide dismutase selectively modulates the activity of Jun-associated transcription factors in fibrosarcoma cells. *Cancer Res* 57, 5265-5271 (1997)

109. Zhao Y, Y. Xue, T. D. Oberley, K. K. Kiningham, S. M. Lin, H. C. Yen, H. Majima, J. Hines & D. St Clair: Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model. *Cancer Res* 61, 6082-6088 (2001)

110. Xu Y, K. K. Kiningham, M. N. Devalaraja, C. C. Yeh, H. Majima, E. J. Kasarskis & D. K. St Clair: An intronic

NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta DNA. *Cell Biol* 18, 709-722 (1999)

111. Kiningham K K, C. Daosukho & D. K. St Clair: IkappaBalpha (inhibitory kappaBalpha) identified as labile repressor of MnSOD (manganese superoxide dismutase) expression. *Biochem J* 384, 543-549 (2004)

112. Djavaheri-Mergny M, D. Javelaud, J. Wietzerbin & F. Besancon: NF-kappaB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFalpha-treated Ewing sarcoma cells. *FEBS Lett* 578, 111-115 (2004)

113. Pizzi M, I. Sarnico, F. Boroni, M. Benarese, N. Steimberg, G. Mazzoleni, G. P. Dietz, M. Bahr, H. C. Liou & P. F. Spano NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. *Cell Death Differ* 12, 761-772 (2005)

114. Yune T Y, S. M. Lee, S. J. Kim, H. K. Park, Y. J. Oh, Y. C. Kim, G. J. Markelonis & T. H. Oh: Manganese superoxide dismutase induced by TNF-beta is regulated transcriptionally by NF-kappaB after spinal cord injury in rats. *J Neurotrauma* 21, 1778-1794 (2004)

115. Vina J, C. Borras, J. Gambini, J. Sastre & F. V. Pallardo: Why females live longer than males? Importance of the upregulation of longevity-associated genes by oestrogenic compounds. *FEBS Lett* 579, 2541-2545 (2005)

116. Brunelle J K, E. L. Bell, N. M. Quesada, K. Vercauteren, V. Tiranti, M. Zeviani, R. C. Scarpulla & N. S. Chandel: Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. *Cell Metab* 1, 409-414 (2005)

117. Wang M, J. S. Kirk, S. Venkataraman, F. E. Domann, H. J. Zhang, F. Q. Schafer, S. W. Flanagan, C. J. Weydert, D. R. Spitz, G. R. Buettner & L. W. Oberley: Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1alpha and vascular endothelial growth factor. *Oncogene* (2005)

118. Ohman T, G. Parish & R. M. Jackson: Hypoxic modulation of manganese superoxide dismutase promoter activity and gene expression in lung epithelial cells. *Am J Respir Cell Mol Biol* 21, 119-127 (1999)

119. O'Brien M L, B. T. Spear & H. P. Glauert: Role of oxidative stress in peroxisome proliferator-mediated carcinogenesis. *Crit Rev Toxicol* 35, 61-88 (2005)

120. Cabrero A, J. C. Laguna & M. Vazquez: Peroxisome proliferator-activated receptors and the control of inflammation. *Curr Drug Targets Inflamm Allergy* 1, 243-248 (2002)

121. Kelly L J, P. P. Vicario, G. M. Thompson, M. R. Candelore, T. W. Doebber, J. Ventre, M. S. Wu, R. Meurer, M. J. Forrest, M. W. Conner, M. A. Cascieri & D. E. Moller: Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. *Endocrinology* 139, 4920-4927 (1998)

122. Medvedev A V, S. K. Snedden, S. Raimbault, D. Ricquier & S. Collins: Transcriptional regulation of the mouse uncoupling protein-2 gene. Double E-box motif is required for peroxisome proliferator-activated receptor-gamma-dependent activation. *J Biol Chem* 276, 10817-10823 (2001)

123. Lin K, J. B. Dorman, A. Rodan & C. Kenyon: daf-16: An HNF-3/forkhead family member that can function to double the life-span of *Caenorhabditis elegans*. *Science* 278, 1319-1322 (1997)
124. Kops G J, T. B. Dansen, P. E. Polderman, I. Saarloos, K. W. Wirtz, P. J. Coffey, T. T. Huang, J. L. Bos, R. H. Medema & B. M. Burgering: Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* 419, 316-321 (2002)
125. Brunet A, A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis & M. E. Greenberg: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 96, 857-868 (1999)
126. Nemoto S & T. Finkel: Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. *Science* 295, 2450-2452 (2002)
127. Hu Y, X. Wang, L. Zeng, D. Y. Cai, K. Sabapathy, S. P. Goff, E. J. Firpo & B. Li: ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. *Mol Biol Cell* 16, 3705-3718 (2005)
128. Wu Z, P. Puigserver, U. Andersson, C. Zhang, G. Adelmant, V. Mootha, A. Troy, S. Cinti, B. Lowell, R. C. Scarpulla & B. M. Spiegelman: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1 *Cell* 98, 115-124 (1999)
129. Vega R B, J. M. Huss & D. P. Kelly: The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. *Mol Cell Biol* 20, 1868-1876 (2000)
130. Yoon J C, P. Puigserver, G. Chen, J. Donovan, Z. Wu, J. Rhee, G. Adelmant, J. Stafford, C. R. Kahn, D. K. Granner, C. B. Newgard & B. M. Spiegelman: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature* 413, 131-138 (2001)
131. Knutti D & A. Kralli: PGC-1, a versatile coactivator. *Trends Endocrinol Metab* 12, 360-365 (2001)
132. Puigserver P: Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. *Int J Obes (Lond)* 29 Suppl 1, S5-9 (2005)
133. Puigserver P, Z. Wu, C. W. Park, R. Graves, M. Wright & B. M. Spiegelman: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* 92, 829-839 (1998)
134. Pilegaard H, B. Saltin & P. D. Neuffer: Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. *J Physiol* 546, 851-858 (2003)
135. Lehman J J, P. M. Barger, A. Kovacs, J. E. Saffitz, D. M. Medeiros & D. P. Kelly: Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. *J Clin Invest* 106, 847-856 (2000)
136. Baar K, A. R. Wende, T. E. Jones, M. Marison, L. A. Nolte, M. Chen, D. P. Kelly & J. O. Holloszy: Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. *Faseb J* 16, 1879-1886 (2002)
137. Puigserver P, J. Rhee, J. Lin, Z. Wu, J. C. Yoon, C. Y. Zhang, S. Krauss, V. K. Mootha, B. B. Lowell & B. M. Spiegelman: Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. *Mol Cell* 8, 971-982 (2001)
138. Handschin C, J. Rhee, J. Lin, P. T. Tarr & B. M. Spiegelman: An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. *Proc Natl Acad Sci U S A* 100, 7111-7116 (2003)
139. Fan M, J. Rhee, J. St-Pierre, C. Handschin, P. Puigserver, J. Lin, S. Jaeger, H. Erdjument-Bromage, P. Tempst & B. M. Spiegelman: Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. *Genes Dev* 18, 278-289 (2004)
140. Huss J M & D. P. Kelly: Nuclear receptor signaling and cardiac energetics. *Circ Res* 95, 568-578 (2004)
141. St-Pierre J, J. Lin, S. Krauss, P. T. Tarr, R. Yang, C. B. Newgard & B. M. Spiegelman: Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. *J Biol Chem* 278, 26597-26603 (2003)
142. Lin J, P. H. Wu, P. T. Tarr, K. S. Lindenberg, J. St-Pierre, C. Y. Zhang, V. K. Mootha, S. Jager, C. R. Vianna, R. M. Reznick, L. Cui, M. Manieri, M. X. Donovan, Z. Wu, M. P. Cooper, M. C. Fan, L. M. Rohas, A. M. Zavacki, S. Cinti, G. I. Shulman, B. B. Lowell, D. Krainc & B. M. Spiegelman: Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. *Cell* 119, 121-135 (2004)
143. Leone T C, J. J. Lehman, B. N. Finck, P. J. Schaeffer, A. R. Wende, S. Boudina, M. Courtois, D. F. Wozniak, N. Sambandam, C. Bernal-Mizrachi, Z. Chen, J. O. Holloszy, D. M. Medeiros, R. E. Schmidt, J. E. Saffitz, E. D. Abel, C. F. Semenkovich & D. P. Kelly: PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis *PLoS Biol* 3, e101 (2005)
144. Valle I, A. Alvarez-Barrientos, E. Arza, S. Lamas & M. Monsalve: PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. *Cardiovasc Res* 66, 562-573 (2005)
145. Moncada S & E. A. Higgs: Endogenous nitric oxide: physiology, pathology and clinical relevance. *Eur J Clin Invest* 21, 361-374 (1991)
146. Bruckdorfer R: The basics about nitric oxide. *Mol Aspects Med* 26, 3-31 (2005)
147. Nisoli E, E. Clementi, C. Paolucci, V. Cozzi, C. Tonello, C. Sciorati, R. Bracale, A. Valerio, M. Francolini, S. Moncada & M. O. Carruba: Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. *Science* 299, 896-899 (2003)
148. Nisoli E, S. Falcone, C. Tonello, V. Cozzi, L. Palomba, M. Fiorani, A. Pisconti, S. Brunelli, A. Cardile, M. Francolini, O. Cantoni, M. O. Carruba, S. Moncada & E. Clementi: Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. *Proc Natl Acad Sci U S A* 101, 16507-16512 (2004)
149. Giulivi C, J. J. Poderoso & A. Boveris: Production of nitric oxide by mitochondria. *J Biol Chem* 273:11038-11043. (1998)

150. Lacza Z, E. Pankotai, A. Csordas, D. Gero, L. Kiss, E. M. Horvath, M. Kollai, D. W. Busija & C. Szabo: Mitochondrial NO and reactive nitrogen species production: Does mtNOS exist? *Nitric Oxide* (2005)
151. Cleeter M W, J. M. Cooper, V. M. Darley-Usmar, S. Moncada & A. H. Schapira: Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. *FEBS Lett* 345, 50-54 (1994)
152. Boveris A, L. E. Costa, J. J. Poderoso, M. C. Carreras & E. Cadenas: Regulation of mitochondrial respiration by oxygen and nitric oxide. *Ann N Y Acad Sci* 899, 121-135 (2000)
153. Brown G C: Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. *Biochim Biophys Acta* 1504, 46-57 (2001)
154. Cooper C E: Competitive, reversible, physiological? Inhibition of mitochondrial cytochrome oxidase by nitric oxide. *IUBMB Life* 55, 591-597 (2003)
155. Moncada S & J. D. Erusalimsky: Does nitric oxide modulate mitochondrial energy generation and apoptosis? *Nat Rev Mol Cell Biol* 3, 214-220 (2002)
156. Brown G C & C. E. Cooper: Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. *FEBS Lett* 356, 295-298 (1994)
157. Shiva S, J. Y. Oh, A. L. Landar, E. Ulasova, A. Venkatraman, S. M. Bailey & V. M. Darley-Usmar: Nitroxia: the pathological consequence of dysfunction in the nitric oxide-cytochrome c oxidase signaling pathway. *Free Radic Biol Med* 38, 297-306 (2005)
158. Brown G C: Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. *FEBS Lett* 369, 136-139 (1995)
159. Riobo N A, E. Clementi, M. Melani, A. Boveris, E. Cadenas, S. Moncada & J. J. Poderoso: Nitric oxide inhibits mitochondrial NADH:ubiquinone reductase activity through peroxynitrite formation. *Biochem J* 359, 139-145 (2001)
160. Lauer N, T. Suvorava, U. Ruther, R. Jacob, W. Meyer, D. G. Harrison & G. Kojda: Critical involvement of hydrogen peroxide in exercise-induced up-regulation of endothelial NO synthase. *Cardiovasc Res* 65, 254-262 (2005)
161. Kojda G & R. Hambrecht: Molecular mechanisms of vascular adaptations to exercise. Physical activity as an effective antioxidant therapy? *Cardiovasc Res* 67(2), 187-197 (2005)
162. Smith R J, J. Agata, C. Xia, L. Chao & J. Chao: Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. *Life Sci* 76(21), 2457-2471 (2005)
163. Coyle J T & P. Puttfarcken: Oxidative stress, glutamate, and neurodegenerative disorders. *Science* 262, 689-695 (1993)
164. Sayre L M, M. A. Smith & G. Perry: Chemistry and biochemistry of oxidative stress in neurodegenerative disease. *Curr Med Chem* 8, 721-738 (2001)
165. Olanow C W & W. G. Tatton: Etiology and pathogenesis of Parkinson's disease. *Annu Rev Neurosci* 22, 123-144 (1999)
166. Schapira A H: Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. *Biochim Biophys Acta* 1410, 159-170 (1999)
167. Beal M F: Mitochondria, oxidative damage, and inflammation in Parkinson's disease. *Ann N Y Acad Sci* 991, 120-131 (2003)
168. Przedborski S., K. Tieu, C. Perier and M. Vila MPTP as a mitochondrial neurotoxic model of Parkinson's disease. *J Bioenerg Biomembr* 36, 375-379 (2004)
169. Uversky V N: Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. *Cell Tissue Res* 318, 225-241 (2004)
170. Berman S B & T. G. Hastings: Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. *J Neurochem* 73, 1127-1137 (1999)
171. Ischiropoulos H & J. S. Beckman: Oxidative stress and nitration in neurodegeneration: cause, effect, or association? *J Clin Invest* 111, 163-169 (2003)
172. Tretter L, I. Sipos & V. Adam-Vizi: Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. *Neurochem Res* 29, 569-577 (2004)
173. The Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell* 72, 971-983 (1993)
174. MacDonald M E & J. F. Gusella: Huntington's disease: translating a CAG repeat into a pathogenic mechanism. *Curr Opin Neurobiol* 6, 638-643 (1996)
175. Feigin A, K. L. Leenders, J. R. Moeller, J. Missimer, G. Kuenig, P. Spetsieris, A. Antonini & D. Eidelberg: Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. *J Nucl Med* 42, 1591-1595 (2001)
176. Panov A V, C. A. Gutekunst, B. R. Leavitt, M. R. Hayden, J. R. Burke, W. J. Strittmatter & J. T. Greenamyre: Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci* 5, 731-736 (2002)
177. Beal M F, E. Brouillet, B. Jenkins, R. Henshaw, B. Rosen & B. T. Hyman: Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. *J Neurochem* 61, 1147-1150 (1993)
178. Beal M F, E. Brouillet, B. G. Jenkins, R. J. Ferrante, N. W. Kowall, J. M. Miller, E. Storey, R. Srivastava, B. R. Rosen & B. T. Hyman: Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. *J Neurosci* 13, 4181-4192 (1993)
179. Brouillet E, P. Hantraye, R. J. Ferrante, R. Dolan, A. Leroy-Willig, N. W. Kowall & M. F. Beal Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. *Proc Natl Acad Sci U S A* 92, 7105-7109 (1995)
180. Brouillet E, F. Conde, M. F. Beal & P. Hantraye Replicating Huntington's disease phenotype in experimental animals. *Prog Neurobiol* 59, 427-468 (1999)
181. Milakovic T & G. V. Johnson: Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. *J Biol Chem* 280, 30773-30782 (2005)

182. Kuhl D E, C. H. Markham, E. J. Metter, W. H. Riege, M. E. Phelps & J. C. Mazziotta: Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. *Res Publ Assoc Res Nerv Ment Dis* 63, 199-209 (1985)
183. Tanzi R E & L. Bertram: Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. *Cell* 120, 545-555 (2005)
184. Chagnon P, C. Betard, Y. Robitaille, A. Cholette & D. Gauvreau: Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. *Neuroreport* 6, 711-715 (1995)
185. Takeda A, M. A. Smith, J. Avila, A. Nunomura, S. L. Siedlak, X. Zhu, G. Perry & L. M. Sayre: In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. *J Neurochem* 75, 1234-1241 (2000)
186. Premkumar D R, M. A. Smith, P. L. Richey, R. B. Petersen, R. Castellani, R. K. Kutty, B. Wiggert, G. Perry & R. N. Kalaria: Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. *J Neurochem* 65, 1399-1402 (1995)
187. Schipper H M: Heme oxygenase-1: role in brain aging and neurodegeneration. *Exp Gerontol* 35, 821-830 (2000)
188. Castellani R J, K. Honda, X. Zhu, A. D. Cash, A. Nunomura, G. Perry & M. A. Smith: Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. *Ageing Res Rev* 3, 319-326 (2004)
189. Maynard C J, A. I. Bush, C. L. Masters, R. Cappai & Q. X. Li: Metals and amyloid-beta in Alzheimer's disease. *Int J Exp Pathol* 86, 147-159 (2005)
190. Hensley K, N. Hall, R. Subramaniam, P. Cole, M. Harris, M. Aksenov, M. Aksenova, S. P. Gabbita, J. F. Wu, J. M. Carney & et al.: Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. *J Neurochem* 65, 2146-2156 (1995)
191. Markesbery W R & M. A. Lovell: Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. *Neurobiol Aging* 19, 33-36 (1998)
192. Lovell M A, C. Xie & W. R. Markesbery: Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. *Neurobiol Aging* 22, 187-194 (2001)
193. Lauderback C M, J. M. Hackett, F. F. Huang, J. N. Keller, L. I. Szveda, W. R. Markesbery & D. A. Butterfield: The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. *J Neurochem* 78, 413-416 (2001)
194. Lin H, R. Bhatia & R. Lal: Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. *FASEB J* 15, 2433-2444 (2001)
195. Dewji N N & C. Do: Heat shock factor-1 mediates the transcriptional activation of Alzheimer's beta-amyloid precursor protein gene in response to stress. *Brain Res Mol Brain Res* 35, 325-328 (1996)
196. Ciallella J R, V. V. Rangnekar & J. P. McGillis: Heat shock alters Alzheimer's beta amyloid precursor protein expression in human endothelial cells. *J Neurosci Res* 37, 769-776 (1994)
197. Cisse S, G. Perry, G. Lacoste-Royal, T. Cabana & D. Gauvreau: Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer's disease brains. *Acta Neuropathol (Berl)* 85, 233-240 (1993)
198. Perez N, J. Sugar, S. Charya, G. Johnson, C. Merrill, L. Bierer, D. Perl, V. Haroutunian & W. Wallace: Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. *Brain Res Mol Brain Res* 11, 249-254 (1991)
199. Hamos J E, B. Oblas, D. Pulaski-Salo, W. J. Welch, D. G. Bole & D. A. Drachman: Expression of heat shock proteins in Alzheimer's disease. *Neurology* 41, 345-350 (1991)
200. Aliev G, M. A. Smith, J. C. de la Torre & G. Perry: Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. *Mitochondrion* 4, 649-663 (2004)
201. Delgado-Escueta A V, W. A. Wilson, R. W. Olsen & R. J. Porter: New waves of research in the epilepsies: crossing into the third millennium. *Adv Neurol* 79, 3-58 (1999)
202. Li L M, F. Cendes, F. Andermann, C. Watson, D. R. Fish, M. J. Cook, F. Dubeau, J. S. Duncan, S. D. Shorvon, S. F. Berkovic, S. Free, A. Olivier, W. Harkness & D. L. Arnold: Surgical outcome in patients with epilepsy and dual pathology. *Brain* 122 (Pt 5), 799-805 (1999)
203. Meldrum B S: Metabolic factors during prolonged seizures and their relation to nerve cell death. *Adv Neurol* 34, 261-275 (1983)
204. Theodore W H: Cerebral blood flow and glucose metabolism in human epilepsy. *Adv Neurol* 79, 873-881 (1999)
205. Greene A E, M. T. Todorova & T. N. Seyfried: Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. *J Neurochem* 86, 529-537 (2003)
206. Shoffner J M, M. T. Lott, A. M. Lezza, P. Seibel, S. W. Ballinger & D. C. Wallace: Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. *Cell* 61, 931-937 (1990)
207. Bruce A J & M. Baudry: Oxygen free radicals in rat limbic structures after kainate-induced seizures. *Free Radic Biol Med* 18, 993-1002 (1995)
208. Lan J, D. C. Henshall, R. P. Simon & J. Chen: Formation of the base modification 8-hydroxyl-2'-deoxyguanosine and DNA fragmentation following seizures induced by systemic kainic acid in the rat. *J Neurochem* 74, 302-309 (2000)
209. Liang L P, Y. S. Ho & M. Patel: Mitochondrial superoxide production in kainate-induced hippocampal damage. *Neuroscience* 101, 563-570 (2000)
210. Melov S, P. Coskun, M. Patel, R. Tuinstra, B. Cottrell, A. S. Jun, T. H. Zastawny, M. Dizdaroglu, S. I. Goodman, T. T. Huang, H. Mizioroko, C. J. Epstein & D. C. Wallace: Mitochondrial disease in superoxide dismutase 2 mutant mice. *Proc Natl Acad Sci U S A* 96, 846-851 (1999)
211. Liang L P & M. Patel: Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease. *J Neurochem* 90, 1076-1084 (2004)
212. Cock H R, X. Tong, I. P. Hargreaves, S. J. Heales, J. B. Clark, P. N. Patsalos, M. Thom, M. Groves, A. H.

- Schapira, S. D. Shorvon & M. C. Walker :Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. *Epilepsy Res* 48, 157-168 (2002)
213. Peterson S L, D. Morrow, S. Liu & K. J. Liu: Hydroethidine detection of superoxide production during the lithium-pilocarpine model of status epilepticus. *Epilepsy Res* 49, 226-238 (2002)
214. Sullivan P G, C. Dube, K. Dorenbos, O. Steward & T. Z. Baram: Mitochondrial uncoupling protein-2 protects the immature brain from excitotoxic neuronal death. *Ann Neurol* 53, 711-717 (2003)
215. Henshall D C, T. Araki, C. K. Schindler, J. Q. Lan, K. L. Tiekoter, W. Taki & R. P. Simon: Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death. *J Neurosci* 22, 8458-8465 (2002)
216. Henshall D C, D. P. Bonislawski, S. L. Skradski, T. Araki, J. Q. Lan, C. K. Schindler, R. Meller & R. P. Simon: Formation of the Apaf-1/cytochrome c complex precedes activation of caspase-9 during seizure-induced neuronal death. *Cell Death Differ* 8, 1169-1181 (2001)
217. Calabrese V, R. Lodi, C. Tonon, V. D'Agata, M. Sapienza, G. Scapagnini, A. Mangiameli, G. Pennisi, A. M. Stella & D. A. Butterfield Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. *J Neurol Sci* 233, 145-162 (2005)
218. Durr A, M. Cossee, Y. Agid, V. Campuzano, C. Mignard, C. Penet, J. L. Mandel, A. Brice & M. Koenig: Clinical and genetic abnormalities in patients with Friedreich's ataxia. *N Engl J Med* 335, 1169-1175 (1996)
219. Campuzano V, L. Montermini, M. D. Molto, L. Pianese, M. Cossee, F. Cavalcanti, E. Monros, F. Rodius, F. Duclos, A. Monticelli, F. Zara, J. Canizares, H. Koutnikova, S. I. Bidichandani, C. Gellera, A. Brice, P. Trouillas, G. De Michele, A. Filla, R. De Frutos, F. Palau, P. I. Patel, S. Di Donato, J. L. Mandel, S. Cocozza, M. Koenig & M. Pandolfo: Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. *Science* 271, 1423-1427 (1996)
220. Campuzano V, L. Montermini, Y. Lutz, L. Cova, C. Hindelang, S. Jiralerspong, Y. Trottier, S. J. Kish, B. Faucheux, P. Trouillas, F. J. Authier, A. Durr, J. L. Mandel, A. Vescovi, M. Pandolfo & M. Koenig: Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. *Hum Mol Genet* 6, 1771-1780 (1997)
221. Babcock M, D. de Silva, R. Oaks, S. Davis-Kaplan, S. Jiralerspong, L. Montermini, M. Pandolfo & J. Kaplan: Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. *Science* 276, 1709-1712 (1997)
222. Koutnikova H, V. Campuzano, F. Foury, P. Dolle, O. Cazzalini & M. Koenig: Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. *Nat Genet* 16, 345-351 (1997)
223. Bradley J L, J. C. Blake, S. Chamberlain, P. K. Thomas, J. M. Cooper & A. H. Schapira: Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. *Hum Mol Genet* 9, 275-282 (2000)
224. Puccio H & M. Koenig: Recent advances in the molecular pathogenesis of Friedreich ataxia. *Hum Mol Genet* 9, 887-892 (2000)
225. Simon D, H. Seznec, A. Gansmuller, N. Carelle, P. Weber, D. Metzger, P. Rustin, M. Koenig & H. Puccio: Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. *J Neurosci* 24, 1987-1995 (2004)
226. Cavadini P, H. A. O'Neill, O. Benada & G. Isaya: Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. *Hum Mol Genet* 11, 217-227 (2002)
227. Yoon T & J. A. Cowan: Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. *J Am Chem Soc* 125, 6078-6084 (2003)
228. Shoichet S A, A. T. Baumer, D. Stamenkovic, H. Sauer, A. F. Pfeiffer, C. R. Kahn, D. Muller-Wieland, C. Richter & M. Ristow: Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation in vitro. *Hum Mol Genet* 11, 815-821 (2002)
229. Oberley L W: Mechanism of the tumor suppressive effect of MnSOD overexpression. *Biomed Pharmacother* 59, 143-148 (2005)
230. Cerutti P A: Prooxidant states and tumor promotion. *Science* 227, 375-381 (1985)
231. St Clair D K, X. S. Wan, T. D. Oberley, K. E. Muse & W. H. St Clair: Suppression of radiation-induced neoplastic transformation by overexpression of mitochondrial superoxide dismutase. *Mol Carcinog* 6, 238-242 (1992)
232. Zhong W, L. W. Oberley, T. D. Oberley & D. K. St Clair: Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. *Oncogene* 14, 481-490 (1997)
233. Van Remmen H, Y. Ikeno, M. Hamilton, M. Pahlavani, N. Wolf, S. R. Thorpe, N. L. Alderson, J. W. Baynes, C. J. Epstein, T. T. Huang, J. Nelson, R. Strong & A. Richardson: Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. *Physiol Genomics* 16, 29-37 (2003)
234. Bolt H M, H. Foth, J. G. Hengstler & G. H. Degen: Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. *Toxicol Lett* 151, 29-41 (2004)
235. Trosko J E & B. L. Upham: The emperor wears no clothes in the field of carcinogen risk assessment: ignored concepts in cancer risk assessment. *Mutagenesis* 20, 81-92 (2005)
236. Dobrovolskaia M A & S. V. Kozlov: Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. *Curr Cancer Drug Targets* 5, 325-344 (2005)
237. Bustamante J, L. Nutt, S. Orrenius & V. Gogvadze: Arsenic stimulates release of cytochrome c from isolated mitochondria via induction of mitochondrial permeability transition. *Toxicol Appl Pharmacol* 207, 110-116 (2005)
238. Liu S X, M. M. Davidson, X. Tang, W. F. Walker, M. Athar, V. Ivanov & T. K. Hei: Mitochondrial damage mediates genotoxicity of arsenic in mammalian cells. *Cancer Res* 65, 3236-3242 (2005)
239. Ko C B, S. J. Kim, C. Park, B. R. Kim, C. H. Shin, S. Choi, S. Y. Chung, J. H. Noh, J. H. Jeun, N. S. Kim & R. Park: Benzo(a)pyrene-induced apoptotic death of mouse hepatoma Hepalclc7 cells via activation of intrinsic

- caspase cascade and mitochondrial dysfunction. *Toxicology* 199, 35-46 (2004)
240. Bartsch H: Studies on biomarkers in cancer etiology and prevention: a summary and challenge of 20 years of interdisciplinary research. *Mutat Res* 462, 255-279 (2000)
241. Kang D & N. Hamasaki: Alterations of mitochondrial DNA in common diseases and disease states: aging, neurodegeneration, heart failure, diabetes, and cancer. *Curr Med Chem* 12, 429-441 (2005)
242. Copeland W C, J. T. Wachsman, F. M. Johnson & J. S. Penta: Mitochondrial DNA alterations in cancer. *Cancer Invest* 20, 557-569 (2002)
243. Modica-Napolitano J S & K. K. Singh: Mitochondrial dysfunction in cancer. *Mitochondrion* 4, 755-762 (2004)
244. Dias N & C. Bailly: Drugs targeting mitochondrial functions to control tumor cell growth. *Biochem Pharmacol* 70, 1-12 (2005)
245. Renschler M F: The emerging role of reactive oxygen species in cancer therapy. *Eur J Cancer* 40, 1934-1940 (2004)
246. Beckman K B & B. N. Ames: Mitochondrial aging: open questions. *Ann N Y Acad Sci* 854, 118-127 (1998)
247. Kirkwood T B & S. N. Austad: Why do we age? *Nature* 408, 233-238 (2000)
248. Balaban R S, S. Nemoto & T. Finkel: Mitochondria, oxidants, and aging. *Cell* 120, 483-495 (2005)
249. Cejkova J, M. Vejrazka, J. Platenik & S. Stipek: Age-related changes in superoxide dismutase, glutathione peroxidase, catalase and xanthine oxidoreductase/xanthine oxidase activities in the rabbit cornea. *Exp Gerontol* 39, 1537-1543 (2004)
250. Genova M L, M. M. Pich, A. Bernacchia, C. Bianchi, A. Biondi, C. Bovina, A. I. Falasca, G. Formigini, G. P. Castelli & G. Lenaz: The mitochondrial production of reactive oxygen species in relation to aging and pathology. *Ann N Y Acad Sci* 1011, 86-100 (2004)
251. Sastre J, F.V. Pallardo & J.Vina: The role of mitochondrial oxidative stress in aging. *Free Radic Biol Med* 35, 1-8 (2003)
252. Terman A, H. Dalen, J. W. Eaton, J. Neuzil & U. T. Brunk: Aging of cardiac myocytes in culture: oxidative stress, lipofuscin accumulation, and mitochondrial turnover. *Ann N Y Acad Sci* 1019, 70-77 (2004)
253. Stadtman E R & R. L. Levine: Protein oxidation. *Ann N Y Acad Sci* 899, 191-208 (2000)
254. Mecocci P, M. F. Beal, R. Cecchetti, M. C. Polidori, A. Cherubini, F. Chionne, L. Avellini, G. Romano & U. Senin: Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. *Mol Chem Neuropathol* 31, 53-64 (1997)
255. Mecocci P, U. MacGarvey & M. F. Beal: Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. *Ann Neurol* 36, 747-751 (1994)
256. Paradies G, F. M. Ruggiero, G. Petrosillo & E. Quagliariello: Age-dependent decline in the cytochrome c oxidase activity in rat heart mitochondria: role of cardiolipin. *FEBS Lett* 406, 136-138 (1997)
257. Hagen T M, D. L. Yowe, J. C. Bartholomew, C. M. Wehr, K. L. Do, J. Y. Park & B. N. Ames: Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. *Proc Natl Acad Sci U S A* 94, 3064-3069 (1997)
258. Muller-Hocker J: Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm of man without muscular disease: an age-related alteration. *J Neurol Sci* 100, 14-21 (1990)
259. Toescu E C, N. Myronova & A. Verkhatsky: Age-related structural and functional changes of brain mitochondria. *Cell Calcium* 28, 329-338 (2000)
260. Coleman R, A. Weiss, S. Finkelbrand & M. Silbermann: Age and exercise-related changes in myocardial mitochondria in mice. *Acta Histochem* 83, 81-90 (1988)
261. Lowell B B & G. I. Shulman: Mitochondrial dysfunction and type 2 diabetes. *Science* 307, 384-387 (2005)
262. Green K, M. D. Brand & M. P. Murphy: Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. *Diabetes* 53 Suppl 1, S110-118 (2004)
263. Dandona P, A. Aljada, A. Chaudhuri, P. Mohanty & R. Garg: Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation* 111, 1448-1454 (2005)
264. Brownlee M: A radical explanation for glucose-induced beta cell dysfunction. *J Clin Invest* 112, 1788-1790 (2003)
265. Glass C K & J. L. Witztum: Atherosclerosis. the road ahead. *Cell* 104, 503-516 (2001)
266. Loscalzo J: Oxidant stress: a key determinant of atherothrombosis. *Biochem Soc Trans* 31, 1059-1061 (2003)
267. Nishikawa T, D. Edelstein, X. L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, M. A. Yorek, D. Beebe, P. J. Oates, H. P. Hammes, I. Giardino & M. Brownlee: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* 404, 787-790 (2000)
268. Jassem W & N. D. Heaton: The role of mitochondria in ischemia/reperfusion injury in organ transplantation. *Kidney Int* 66, 514-517 (2004)
269. Honda H M, P. Korge & J. N. Weiss: Mitochondria and ischemia/reperfusion injury. *Ann N Y Acad Sci* 1047, 248-258 (2005)

Key Words: Neurological Diseases, Parkinson Disease, Alzheimer Disease, Huntington Disease, Epilepsy, Atherosclerosis, Diabetes, Cancer, Aging, Review

Send correspondence to: María Monsalve, PhD. Centro Nacional de Investigaciones Cardiovasculares, Instituto de Salud Carlos III, Melchor Fernandez Almagro 3, 28029-Madrid, Spain, Tel: 34-914531200 ext. 2009, Fax. 34-914531245, E-mail: mmonsalve@cnic.es

<http://www.bioscience.org/current/vol12.htm>